WO2008077406A2 - Couplage d'éléments - Google Patents

Couplage d'éléments Download PDF

Info

Publication number
WO2008077406A2
WO2008077406A2 PCT/DK2007/000569 DK2007000569W WO2008077406A2 WO 2008077406 A2 WO2008077406 A2 WO 2008077406A2 DK 2007000569 W DK2007000569 W DK 2007000569W WO 2008077406 A2 WO2008077406 A2 WO 2008077406A2
Authority
WO
WIPO (PCT)
Prior art keywords
disulfide bridge
protein
support
molecule
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2007/000569
Other languages
English (en)
Other versions
WO2008077406A3 (fr
Inventor
Maria Teresa Petersen
Steffen Bjørn PETERSEN
Laurent Duroux
Meg Duroux
Esben Skovsen
Jon Weis Stranddorf
Rasmus Lybech Jensen
Lars Wagner STÄDE
Rune Wiik Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aalborg Universitet AAU
BionanoPhotonics AS
Original Assignee
Aalborg Universitet AAU
BionanoPhotonics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aalborg Universitet AAU, BionanoPhotonics AS filed Critical Aalborg Universitet AAU
Publication of WO2008077406A2 publication Critical patent/WO2008077406A2/fr
Publication of WO2008077406A3 publication Critical patent/WO2008077406A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Definitions

  • the present invention relates to a method of coupling two elements. More particular, the invention concerns a method of coupling molecules, proteins, peptides or peptide-containing elements to a support or to a second molecule, protein, peptide or peptide-containing element, where the structural and functional properties of the coupled or immobilised elements are preserved, and the orientation of coupling can be controlled on a molecular scale.
  • Molecules can be immobilised on a support, carrier or solid surface either passively through hydrophobic or ionic interactions, or covalently by attachment to activated surface groups.
  • immobilisation for solid phase chemistry and biological screening, the analytical uses of the technology have been widely explored.
  • the technology has found broad application in many different areas of biotechnology, e.g. diagnostics, biosensors, affinity chromatography and immobilisation of molecules in immunoassays, such as ELISA.
  • the value of immobilisation technology is demonstrated by the recent development of DNA microarrays, where multiple oligonucleotide or cDNA samples are immobilised on a solid surface in a spatially addressable manner.
  • Other functional groups on the surface of proteins which can be used for attachment to an appropriate surface include reacting an amine with an aldehyde via a Schiff-base, cross-linking amine groups to an amine surface with gluteraldehyde to form peptide bonds, cross-linking car- boxylic acid groups present on the protein and support surface with car- bodiimide, cross-linking based on disulfide bridge formation between two thiol groups and the formation of a thiol-Au bond between a thiol group and a gold surface.
  • N- hydroxysuccinimide esters are formed from a fraction of the carboxyl groups of the carboxymethyldextran matrix via reaction with N-hydroxysuccinimide (NHS) and N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride (EDC) in water, which then react spontaneously with amine groups on a protein to form covalent bonds (Johnsson B., et. a/., 1991 , Anal Biochem 198:268-77).
  • NHS N-hydroxysuccinimide
  • EDC N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride
  • Mutant plastocyanin expressed intracellularly in bacteria, is exposed to a reduc- ing environment in the cytoplasm, such that the inserted cysteines are reduced, and can thus mediate the direct adsorption of the isolated protein onto a gold substrate.
  • the thiol group binding properties of the protein are thus dependent on in vivo or in vitro chemical reduction of the cysteine residues on the surface of the protein.
  • An alternative approach to engineering thiol-group binding properties into a protein has been described for ribonuclease (RnaseA), which has four essential cystines (Sweeney, R.Y. et al. 2000 Anal Biochem. 286: 312-314).
  • a method for orientated, light-dependent, covalent immobilization of proteins on a solid support, using the heterobifunctional wetting-agent N-[m-[3- (trifluoromethyl)diazirin-3-yl]phenyl]-4-maleimidobutyramine, is described in WO 91/16425 and by Collioud A et al. (1993) in Bioconjugate Chem. 4: 528- 536.
  • the aryldiazirine function of this cross-linking reagent facilitates light- dependent, carbene-mediated, covalent binding to either inert supports or to biomolecules, such as proteins, carbohydrates and nucleic acids.
  • the maleimide function of the cross-linker allows binding to a thiolated surface by thermochemical modification of cysteine thiols. Orientated binding of this cross-linking reagent to a protein can be attained by a thermochemical interaction between the maleimide function and an exposed thiol group on the protein surface, however this treatment may modify the structure and activity of the target protein.
  • Light-induced covalent coupling of the cross-linking reagent to a protein via the carbene function has the disadvantage that it does not provide for controlled orientation of the target protein.
  • thermochemical/chemical steps sometimes with hazardous chemicals, some of which are likely to have a deleterious effect on the structure and/or function of the bound protein.
  • hazardous chemicals some of which are likely to have a deleterious effect on the structure and/or function of the bound protein.
  • the available methods are often inva- sive, whereby foreign groups are introduced into a protein to act as functional groups, which cause protein denaturation, as well as lower its biological activity and substrate specificity.
  • Disulphide bridges are known to be excellent quenchers of excited-state aromatic residues. Any aromatic residue, which is in close spatial proximity, can cause photo-induced disruption of a neighbouring disulphide bridge. Hence, the three aromatic amino acids, tryptophan, tyrosine and phenylalanine found in proteins, are all potential mediators of light-induced disulphide bridge disruption. While irradiation with light of a range of wavelengths ex- tending from 240 nm to 300 nm will excite all aromatic residues, the individual aromatic residues have differing absorption maxima (Table 1 ; data obtained at neutral pH).
  • electronic excitation of tryptophan can both be achieved with ultraviolet light at 295 nm, or with two-photon excitation at a wavelength of approximately 690 nm.
  • excited tyrosine residues can cause the excitation of neighbouring tryptophan residues by a mechanism called fluorescence resonance energy transfer, which in turn can cause disulphide bridge disruption.
  • disulphide bridges When proteins are exposed to UV irradiation, some disulphide bridges are disrupted to form activated thiols. Although disulphide bridges are commonly found in the structural core and near/on the surface of folded proteins, those located in close proximity to aromatic amino acids are the most susceptible to UV-induced disruption. During UV exposure of proteins, energy absorbed by side chains of aromatic amino acid residues is transferred to spatial neighbouring disulphide bridges, which function as quenchers (Neves- Petersen MT., et al., 2002, Protein Science 11 : 588-600). However, the flow of energy transferred to disulphide bridges and the likely formation of intermediate chemical species such as radicals/ions formed upon light excitation of the sample ultimately serves to trigger their disruption.
  • WO 04/065928 provides a method of coupling a protein to a support by inducing the formation of thiol groups in the protein with irradiation, and coupling the protein to the support.
  • the formation of thiol group(s) in the protein is a consequence of the disruption of disulfide bridges following electronic excitation of aromatic amino acid residues located in close spatial proximity to the disulfide bridge.
  • the light-induced coupling method facilitates the orientated immobilization of a protein on a support.
  • a prerequisite condition for obtaining the desired immobilisation is the existence of an essential triad, comprising an aromatic amino acid in close approximation to a disulfide bridge, in the protein. The contents of this application are included herein as reference.
  • Danish patent application PA 2005 00925 discloses a method of coupling a protein to a support by inducing the formation of thiol groups in the protein and in said support, where the support comprises disulfide bridge- containing triad-containing linkers on the surface of a support. The contents of this application are included herein as reference.
  • the present invention satisfies the need in the art for coupling of two elements or immobilisation of molecules on a supports, where the structural and functional properties of the coupled or immobilised elements or molecules can be preserved if desired, and the orientation of coupling can be controlled on a molecular scale.
  • WO 04/065928 the exploitation of appropriate naturally occurring triads for coupling of a molecule to a support or another molecule by thiol binding is disclosed.
  • a triad is present when a disulfide bridge is located in sufficient proximity ( ⁇ 10 A) to an aromatic amino acid residue in the folded pro- tein, to allow for an absorption and quenching by disruption of the disulfide bridge of energy emission from light irradiated aromatic aminos.
  • the thiol groups created in proteins in this way by light-induced disulfide bridge disruption may then used to immobilise the protein to a support in an orientation- dependent and controlled manner.
  • the present invention addresses the problem of coupling molecules and supports to other molecules or support, which molecules and/or support do not contain appropriate naturally occurring triad(s).
  • the natural protein may not contain a triad or the triad(s) present is/are not accessible by light, or the created thiol(s) is/are not accessible for coupling because it is buried inside the protein or breakage of the disulfide bond will destroy the properties of the protein, such at binding capacity or enzymatic activity or the like.
  • an appropriate disulfide bridge-containing triad advantageously may be added or providing to the protein. Similar for peptides and polypeptides to be coupled to another element.
  • the present invention also provides for coupling of two supports or two molecules both lacking appropriate thiol-binding properties, by utilizing the present principle of adding or providing appropriate disulfide bridge-containing triads.
  • the principle can also be used to coupling of more than two elements.
  • the principle may further be used to add the aromatic amino acid in a solution to the element(s) comprising an appropriate disulphide bridge.
  • the present invention relates to a method of providing an appropriate disulfide bridge-containing triad to an element A which lacks such appropriate triad for coupling element A to an element B via thiol binding.
  • the invention also relates to a method of providing an appropriate disulfide bridge to element A and to methods of additional provision of appropriate disulfide bridge- containing triad or disulfide bridge to element B.
  • the present invention relates to a method of coupling two elements A and B, by
  • Elements according to the invention comprise molecules and supports, thus providing great flexibility, allowing for coupling combinations of molecule + molecule, support + support, molecule + support and/or support + molecule.
  • different, similar or identical support(s) and/ molecule(s) can be coupled.
  • two or more elements placed on the same object may be coupled in order to create a desired conformation of the object, which may be a support or a molecule such as a protein or polypeptide.
  • the molecule is a biomolecule, such as a peptide, a protein, a polynucleotide, a lipid, a sugar, a pharmaceutical, a cosmetical, a pro-drug and the like.
  • the invention is not limited to proteins, but allows virtually any molecule(s) and support to be coupled according to the invention, provided that an appropriate disulfide bridge or disulfide bridge- containing triad can be provided, for example by covalent attachment and/or by genetic engineering.
  • a support according to the invention comprises a soluble, semi- soluble or insoluble material to which an appropriate disulfide bridge or disul- fide bridge-containing triad is capable of being attached.
  • Such a support may also comprise a thiol reactive surface or a surface that can be made thiol reactive, e.g. a surface comprising gold or quarts.
  • a support which is reactive for binding one or more molecule(s) is denoted "a carrier".
  • a carrier may therefore be a support which by nature is reactive for binding one or more molecule(s) containing a thiol group or a support which is made reactive for binding one or more molecule(s) via thiol binding.
  • Another aspect of the invention relates to a linker molecule comprising an appropriate disulfide bridge or disulfide bridge-containing triad, which may be provided to an element lacking an appropriate disulfide bridge or disulfide bridge-containing triad.
  • Such an appropriate linker molecule may comprise one or more copies of a peptide comprising any of the formulas (I) X1 m C X2 n C X3o 0 X4 P , (II) X1 m C X2 n 0 X3 0 C X4 P and/or (III): X1 m 0 X2 n C X3 0 C X4 P , wherein X1 m , X2 n , X3 0 and X4 P represent the same or different peptides, each peptide respectively consisting of m, n, o, and p amino acids, where m, n, o and p are mutually independent numbers between 0 and 1000 (or 100, 25,or 10), and m + n + o + p ⁇ 1000 (or 100, 25, or 10), said amino acids being selected from all natural and synthetic amino acids, C is cysteine, and the two cysteines are covalently joined
  • the linker is provided to an element, support, molecule and/or protein, polypeptide or peptide through covalent binding of a linker molecule, e.g using NHS (N-hydroxysuccinimide), EDC (N-ethyl-N 1 - (dimethylaminopropyl) carbodiimide hydrochloride), activated ester, maleim- ide, disulfide formation, streptavidin/biotin, activated alcohol, vinylsulfone, Schiff base formation and/or "click” chemistry and the like.
  • NHS N-hydroxysuccinimide
  • EDC N-ethyl-N 1 - (dimethylaminopropyl) carbodiimide hydrochloride
  • activated ester e.g using NHS (N-hydroxysuccinimide), EDC (N-ethyl-N 1 - (dimethylaminopropyl) carbodiimide hydrochloride), activated ester, maleim- ide, dis
  • a linker providing an appropriate disulfide bridge and/or disulfide bridge-containing triad is provided through genetic engineering techniques, comprising: (i) N-terminal extension, (ii) C-terminal extension, (iii) internal extension, (iv) amino acid substitution, (v) amino acid insertion, (vi) amino acid deletion or (vii) any combination or combinations of said methods (i-vi).
  • genetic engineering may also result in a conformation change in a molecule, thereby bringing an aromatic amino acid and an appropriate disulphide bridge in the vicinity of each other.
  • coupling of two elements may be pro- vided by adding a free aromatic amino acid (in solution), either alone or being part of a molecule, to the vicinity of one or more appropriate disulfide bridges.
  • the invention provides an irradiation step, comprising light of a wavelength that excites one or more aromatic amino acids.
  • Such wavelength interval(s) comprises UV light in the wavelength interval of 250 to 305 nm (or 250 to 260nm, 270 to 280 nm and/or 290 to 300nm, or about 254, 275 or 295 nm), or with light having longer wavelengths that by means of non-linear processes and/or multiphoton excitation promotes the same electronic transitions as light in said wavelength interval of 250 to 305 nm.
  • An aspect of the invention provides a coupling between elements, resulting in an immobilization on a support or surface, which can be spatially controlled as disclosed in WO 04/065928.
  • a support and/or surface may also be a derivatized support that is capable of binding a thiol group, such as a support and/or surface comprising a thiol group or a disulfide bridge.
  • a surface or support may comprise a spacer.
  • a further aspect of the present invention relates to a magnetic (nano)particle or a cantilever for atomic force microscopy, where the magnetic (nano)particles or a cantilever comprises a molecule coupled by irradiation of a disulfide bridge or disulfide containing triad.
  • dimers such as homo- or heterodimers, consisting of two identical or different elements or subunits.
  • dendrimers such as homo- or hetero den- drimers.
  • a further aspect relates to a vector or plasmid providing an appropriate disul- fide bridge or triad fused to the N- or C-terminus of a protein to be expressed by said vector or plasmid in an appropriate host.
  • Another aspect relates to a vector or plasmid that provides an appropriate disulfide bridge or triad by fusion of a protein by C- or N-terminal fusion to a protein or part thereof or a natural or synthetic polypeptide or peptide.
  • a useful linker polypeptide is knottin (HpTX2) and/or mutant knot- tin (mutHpTX2).
  • Figure 1 illustrates different embodiments of the invention concerning irradiation-mediated coupling of two elements (elements, supports and/or mole- cules A and B) where a linker is provided to element A or two linkers, L A and L B , are provided to elements A and B, respectively.
  • C cysteine
  • Figure 4 Cartoons of the B-FABP structure obtained by Balendiran et al. (2000) using X-ray diffraction with a resolution of 2.80 A (PDB: 1 FE3).
  • FIG. 5 W6/SS cross-linked B-FABP, labeled with 5(6)- carboxynaphthofluorescein, immobilized on thiol derivatized quartz slides using UV (280nm); A: 5 X 5 array; B: 9 X 1 array.
  • Figure 6 X 5 array of SS tagged B-FABP labeled with 5(6)- carboxynaphthofluorescein, immobilized on thiol derivatized quartz slides us- ing UV (280nm).
  • Figure 7 A schematic representation of the structural motif found in knottin peptides.
  • Figure 9 shows different embodiments of the invention regarding dendrimer units before coupling (SS0 x , SS0 y , SS0 z : identical or different triads used for coupling; L a , L b , L c : identical or different linkers):
  • Figure 10 Ion exchange chromatogram of Human B-FABP after refolding.
  • Figure 11 Agarose gel of PCR product of SS tagged B-FABP to determine the optimal annealing temperature.
  • Figure 12 Agarose gel with the colony PCR products containing SS tagged B-FABP.
  • Figure 13 SDS-PAGE gel with SS tagged B-FABP, W6/SS cross linked B- FABP, and native B-FABP.
  • Figure 14 Emission measurements from 300 - 400 nm of native and W6/SS Cross linked B-FABP prior to heating.
  • Figure 15 Emission measurements from 300 to 400 nm of native and W6/SS Cross linked BFABP after heating and subsequent cooling.
  • Figure 16 Temperature scans of native and W6/SS Cross linked B-FABP.
  • Figure 17 Emission scans of 5 ⁇ M Native and 7 ⁇ M SS Tagged B-FABP at pH 5.86 and a temperature of 11.5°C.
  • Figure 18 Emission scans of 7 ⁇ M SS tagged B-FABP before and after heating.
  • Figure 20 Static light scattering of W6/SS cross linked B-FABP prior to and after heating and subsequent cooling.
  • Figure 21 Scattering scan of SS tagged B-FABP at 11.5 0 C.
  • FIG. 22 Structure of HpTX2 (left: Native HpTX2;. middle: mutHpTX2; right: distances from W to each disulfide bridge).
  • Figure 23 The two figures show a possible conformation of HpTX2 after mu- tation of Tyr20 ⁇ Trp20 and Trp25 ⁇ Phe25.
  • Figure 24 Another two possible conformations of HpTX2 after mutation of Tyr20 ⁇ Trp20 and Trp25 ⁇ Phe25.
  • FIG. 26 Schematically illustration of a method and apparatus for material deposition by light induced molecular immobilization. Shown is a light source (102) in the form of a laser.
  • element as used herein is set out to encompass all kinds of molecules, particles and solid supports which are the two or more objects to be coupling by thiol binding.
  • the term "support” comprises a soluble, semi-soluble or insoluble material to which an appropriate disulfide bridge or disulfide bridge- containing triad is capable of being attached.
  • surface For insoluble and solid supports may also be used the term "surface".
  • an insoluble support is electronic chips, slides, wafers, particles, resins, wells, tubes or membranes which include but are not limited to any material comprising polymers such as Topaz, polystyrene, polyethylene, polyester, polyethermides, polypropylene, polycarbonate, polysulfone, polymethylmethacrylate [PMMA], poly(vinylidene flouride) [PVDF], siliciumoxidecontaining materials such as silicon; diamond; glass e.g.
  • a soluble support are a soluble compound or polymer such as hydrocarbons or another biomolecule, for example collagen or a polypeptide, or a magnetic particle.
  • a support can also be a polypeptide or another biomolecule such as DNA or synthetic biomolecules such as aptamers.
  • carrier refers to a support which is or is made re- active for binding one or more molecules.
  • disulfide bridge refers to a disulfide bridge susceptible of being broken by irradiation when in vicinity of an aromatic amino acid and placed in a desired part or region of the element.
  • disulfide bridges may be provided via two cysteines.
  • Disulfide bridges may be intra molecular (part of the same molecule) or inter molecular (covalently linking to peptides, polypeptides or proteins) via a disulfide bridge.
  • the terms "appropriate triad” and “appropriate disulfide bridge-containing triad” refers to a spatial configuration of a disulfide bridge and an aromatic amino acid, which are in sufficient vicinity to each other to allow irradiation-mediated breakage of the disulfide bond and placed or situated in a desired part or region of the element.
  • disulfide bridge and aromatic amino acid are "spatial neighbours”.
  • the element e.g. the protein
  • the thiol group is buried in the interior of the protein, ruins the property, e.g. binding capacity or enzymatic activity, of the protein or cannot be used to secure a desired uniform spatial configuration on a support.
  • spatial neighbours relates to the physical distance between two chemical groups within a compound or composition, such that groups lying in three- dimensional close proximity are considered to be spatial neighbours.
  • a disul- phide bridge in e.g. a protein which is a spatial neighbour to an aromatic residue may function as a quencher for excitation energy absorbed by the aromatic amino acid following irradiation.
  • the physical distance between half cystines of a disulphide bridge, which are spatial neighbours to one or more aromatic residues such as tryptophan residues and may act as quenchers, can be, but is not limited, to a range of 1 to 15 A, more particular 1-12 A or 1- 10 A.
  • reactive thiol group relates to a thiol group which is capable of covalent coupling to another thiol group creating a disulphide bond.
  • the linker used in the method according to the invention is designed so it is activated by irradiation e.g. UV-beam illumination and thereby making spatially controlled immobilisation possible.
  • irradiation e.g. UV-beam illumination
  • This is an advantage of the present method compared to known methods for spot-size immobilisation using UV- beam immobilisation where the support, carrier or surface is capable of bind- ing without activation.
  • known spot-size immobilisation methods may allow polypeptide that were activated above the surface to diffuse to an area outside the UV-beam and be immobilised.
  • immobilisation now requires activation of the support and/or carrier.
  • Activated polypeptide that diffuses outside the immobilisation area will not immobilise because the surface outside the UV-beam area is not activated using the present method.
  • linker relates to a molecule to be provided to an element, e.g. to a molecule or a support, in order to provide to said element a disulfide bridge or disulfide bridge-containing triad capable of being activated by irradiation to contain reactive thiol group(s) (-SH group(s)). When activated, the thiol group should preferably be available for coupling according to the invention.
  • a linker comprising an appropriate disulfide bridge and/or disul- fide bridge-containing triad may include, but is not limited to a linker comprised solely or partly by amino acids.
  • a linker may include other mole- cules than amino acids and may be comprised by one or more peptide groups and one or more groups of organic or non-organic materials, e.g. containing a peptide group and one or more carbohydrate groups, including small sugar molecules, oligosaccharides, large carbohydrate-based poly- mers.
  • Inorganic part(s) of the linker may include e.g. metallic groups based on gold, silver, aluminium, silicon, and/or non-metallic groups based e.g. on ceramic.
  • amino acid comprises both natural amino acids such as Ala (alanine), Cys (cysteine), Asp (aspartic acid), GIu (glutamic acid), Phe (phenylalanine), GIy (glycine), His (histidine), lie (isoleucine), Lys (lysine), Leu (leucine), Met (methionine), Asn (asparagines), Pro (praline), GIn (glutamine), Arg (arginine), Ser (serine), Thr (threonine), VaI (valine), Trp (tryptophan), Tyr (tyrosine) and synthetic or modified amino acids such as Aad (2-aminoadipic acid), bAad (3-Aminoadipic acid), bAla (beta-alanine, beta-aminopropionic acid), Abu (2-aminobutyric acid), 4Abu (4-aminobutyric acid, piperidinic acid), Acp (6-
  • the aromatic amino acids according to the invention comprise phenylalanine, tryptophan and/or tyrosin and/or their derivatives. These derivatives do not significantly alter the excitation/emission behaviour.
  • the terms "peptide” and “polypeptide” are in the present context intended to mean molecules comprising amino acids covalently linked via peptide bonds, and the term encompasses both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 10 to 20 amino acid residues, and polypeptides of more than 20 amino acid residues, for example 25, 30, 50, 100, 200 or even 1000 amino acid residues.
  • the peptides mav be natural occurring or synthesized.
  • the term is also intended to include proteins, i.e.
  • polypeptides comprising at least one polypeptide; when comprising at least two polypeptides, these may form complexes, be covalently linked, or may be non-covalently linked.
  • the polypeptide(s) in a protein can be glycosylated and/or lipidated and/or comprise prosthetic groups.
  • polypeptides includes enzymes, antibodies, antigens, transcription factors, immunoglobulin, binding proteins e.g. DNA binding proteins, or protein domains or fragments of proteins or any other amino acid based material.
  • polyamino acid denotes a molecule constituted by at least 3 covalently linked amino acid residues. The terms may also relate to functional parts or fragments of proteins. Such function may be as providing an appropriate disulfide bridge or disulfide bridge-containing triad or binding, enzy- matic or other biological activity.
  • UV light or “irradiation” or UV illumination” or “UV irradiation” are a range of wavelengths or a single wavelength of UV or visible light. Furthermore, these terms comprise any wavelength that by means of non-linear effects and/or multiphoton excitation will excite aromatic amino acid residues electronically. These aromatic amino acids residues comprise phenylalanine, tryptophan and tyrosine.
  • click chemistry re- fers to methods of linking different molecules as described in "Diverse
  • biosensor comprises an analytical devise incorpo- rating biological or biologically-derived sensing elements, such as an amino acid (e.g., cysteine), protein, antibody, nucleic acid, microorganism or cell.
  • the sensing element is either integrated within or intimately associated with a physicochemical transducer.
  • the general aim of a biosensor is to produce either discrete or continuous signals that are proportional to a single analyte or a related group of analytes such as e.g. digital electronic signals or light signals.
  • the term "pharmaceutical drug” comprises articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and articles (other than food) intended to affect the structure or any function of the body of man or other animals and articles intended for use as a component of any article specified above.
  • nanoparticle refers to (i) "a particle having one or more dimensions of the order of 10Onm or less", (ii) “an aggregate of anywhere from a few hundred to tens of thousands of atoms that combine into a crystalline form with a diameter ranging from 3 -25 nanometers", and/or (iii) “a microscopic, nanoscale particle whose size is measured in nanometers”. Nanoparticles are often used in medical applications acting as drug carriers or imaging agents.
  • the term "dimer” refers to a structure consisting of to monomers, subunits or elements. These may be coupled by a thiol group or disulfide bridge according to the invention. In case of identical subunits, this dimer is also called “homo-dimer”, in contrast to a “hetero-dimer”, which consists of two different subunits. These subunits are not limited to molecules, but can also comprise any elements according to the invention.
  • the term "dendrimer” relates to a tree-like structure, consist- ing of elements or subunits.
  • the subunits or elements are not limited to molecules, but can also comprise one or more elements according to the invention.
  • the dendrimer may comprise similar or different elements and/or subunits. These subunits may be coupled by one or more thiol groups or disulfide bridge(s) according to the invention.
  • the building block/units of the dendrimer may contain several branching points. These may also contain one or more coupling units and/or branching points that are different from those provided by appropriate disulfide bridges and/or disulfide bridge- containing triads according to the invention.
  • the present invention relates to a method of providing an appropriate disulfide bridge-containing triad to an element A which lacks such appropriate triad for coupling element A to an element B via thiol binding.
  • the invention also relates to a method of providing an appropriate disulfide bridge to ele- ment A and to methods of additional provision of appropriate disulfide bridge- containing triad or disulfide bridge to element B. Coupling is achieved while preserving the native structural and functional properties of the coupled elements.
  • the present invention relates to the a method of coupling two element A and B, by
  • Elements according to the invention are molecules and supports, either different or identical, allowing for all permutations, such as A and B are molecules, A is a molecule and B is a support, A and B are supports, and A is a support and B is a molecule; in case of molecule-molecule or support- support couplings, these can be either identical or different.
  • Elements according to the invention comprise molecules and supports, thus providing great flexibility, allowing for coupling combinations of molecule + molecule, support + support, molecule + support and/or support + molecule.
  • the molecule is a biomolecule, such as a peptide, a protein, a polynucleotide, a lipid, a sugar, a pharmaceutical, a cosmetical, a pro- drug and the like.
  • the invention is not limited to proteins, but allows virtually any molecule(s) and support to be coupled according to the invention, provided that an appropriate disulfide bridge or disul- fide bridge-containing triad can be provided, for example by covalent attachment and/or by genetic engineering.
  • a support according to the invention comprises a soluble, semi-soluble or insoluble material to which an appropriate disulfide bridge or disulfide bridge-containing triad is capable of being attached.
  • Such a support may also comprise a thiol reactive surface or a surface that can be made thiol reactive, e.g. a surface comprising gold.
  • a support which is made reactive for binding one or more molecule(s) is denoted "a carrier".
  • the present invention describes a method, where an element is modified in such a way that it can react with another element to form a covalent coupling upon irradiation.
  • the method according to the invention involves attachment of a linker providing an appropriate disulphide bridge or disulfide bridge- containing triad, which is convertible by irradiation to contain fully reactive thiol(s) capable of coupling a desired element (support or molecule), said element containing at least one reactive thiol group or at least one disulphide bridge capable of being activated by irradiation to reactive thiol groups.
  • a particular advantage of the present invention is its avoidance of the several disadvantages associated with the chemical generation of free thiols in a protein.
  • Some proteins e.g., cutinase, are inactivated by the reducing agents (DTT or beta-mercaptoethanol) used to generate free thiols.
  • DTT reducing agents
  • beta-mercaptoethanol beta-mercaptoethanol
  • a reducing agent comprising a thiol group is used to chemically generate free thiols in a protein, it must be removed before immobilisation by can be performed, during which step the disulfide bonds can reform.
  • Alternative reducing agents such as 2-carboxyethyl)phosphine, lacking a thiol group, have the disadvantage that they are reactive to other groups.
  • reducing agents to disrupt disulfide bonds has the additional disadvantage that they are pH de- pendent, both with regards their chemical stability and their reducing activity.
  • the orientation of the immobilised element, such as a polypeptide can be controlled in a uniform and reproducible manner.
  • elements A or B or elements A and B comprise a linker molecule, containing an appropriate disulphide bridge or disul- phide bridge-containing triad, and the elements are activated by irradiation to create reactive thiol groups in the same step or sequentially.
  • the element, molecule or support may comprise one or more disulphide bridges or reactive thiols and the disulphide linker may after irradiation thus be coupled to the molecule or support with either one or more disulphide bonds.
  • the molecule or support comprises one disulphide bridge, and said molecule or support are irradiated simultaneously with the linker contain- ing molecule to create reactive thiol groups.
  • the free thiols in said molecule or support are formed after chemical treatment e.g. using a disulphide reducing agent such as DTT.
  • Another aspect of the invention relates to a linker molecule comprising an appropriate disulfide bridge or disulfide bridge-containing triad, which may be provided to an element lacking an appropriate disulfide bridge or disulfide bridge-containing triad.
  • Figure 1 illustrates a variety of different embodiments of the invention concerning irradiation-mediated coupling of two elements (elements, supports and/or molecules), where a linker L A is provided to an element A, or a linker L A and a linker L B are provided to both elements.
  • these embodiments comprise: (a) A linker L is provided to element A, thus generating element A*, which is now capable of being coupled to element B; (b) A linker LA is provided to element A, and a linker L B : is provided to element B, thus generating elements A* and B*, which are now capable of being coupled; (c) Element A comprising a linker L is coupled to a support; (d) Element A comprising a linker L A is coupled to a support B via a linker L 8 provided to support B; (e) Support A comprising a linker L is coupled to a support B; (f) Support A comprising a linker LA is coupled to a support B via a linker L B provided to support B; (g) A linker L is pro- vided to element A, which is now capable of being coupled to element B; elements A and B are part of the same structure; (h) A linker L A is provided to element A, and a linker L B is provided to element B
  • elements A and B can be part of a common structure, such as part of a support, (e.g. carrier, surface and the like), and/or part of a molecule).
  • a support e.g. carrier, surface and the like
  • the structure may be bent or twisted.
  • the support comprises a foil-like structure, which can be bent or folded, and remains bent or folded after coupling.
  • a linker peptide comprises one or more copies of a peptide comprising any of the formulas: (I) X1 m CX2 n CX3 0 0 X4 P) (II) X1 m CX2 n 0X3 0 CX4p,
  • amino acids being selected from all natural and synthetic amino acids
  • C is cysteine, both the two cysteines are covalently joined by a disulfide bridge
  • 0 is an aromatic amino acid such as phenylalanine, tryptophane or tyrosine, or their derivatives; or 0 represents a peptide bond.
  • the different polypeptides X1 m , X2 n , X3 0 and X4 P do not comprise an additional reactive thiol group.
  • one or more aromatic amino acids are present in the different polypeptides X1 m , X2 n , X3 0 and X4 P .
  • part of the linker When the linker is activated by irradiation to contain reactive thiol groups, part of the linker may be set free (a leaving group) as a by-product.
  • the by- product (or leaving group) will usually be washed away from the surface if they interfere with subsequent reactions.
  • the free thiol group still part of the linker can participate in the formation of a new disulphide bond to a free thiol in the polypeptide.
  • the linker is designed so as to not leave any by-product.
  • the linker is designed so to contain a leaving group.
  • the peptide linker comprises one or more of the formula
  • L is attached to the support and comprises at least one amino acid which does not contain a reactive thiol and which is different from an amino acid which is capable of being activated by irradiation to contain at least one reactive thiol group
  • D is a non-cyclic sequence of amino acids or a cyclic sequence of amino acids, which non-cyclic or cyclic sequence comprises at least two cysteines (C) covalently joined by a disulphide bridge and wherein one of the cysteines (C) is bound to L.
  • the two cysteines (C) are covalently joined by a disulphide bridge (-C-S-S-C-).
  • they are covalently joined by a disulphide bridge and also by a peptide bond (-C-C-).
  • the peptide linker comprises at least one aromatic amino acid which may be part of either D or L.
  • neither D nor L contains an aromatic amino acid.
  • L comprises 1-30 amino acids, 3-20 amino acids or 5-10 amino acids.
  • D comprises 2-30 amino acids, 3-20 amino acids or 5-10 amino acids.
  • L comprises one or more aromatic amino acids, such as phenylalanine, tryptophane, tyrosine or their derivatives.
  • L comprises an aromatic amino acid separated from the cysteine (C) in D bound to L by at least one amino acid.
  • D is a cyclic sequence of amino acids.
  • D has the following sequence C(X) n C, wherein X independently is any amino acid which does not comprise a reactive thiol group, n is from 1 to 10, 2 to 8 or 3 to 6, and the two cysteines (C) are covalently joined by a disulphide bridge.
  • D has the following sequence CC(Xi )m, wherein Xi independently is any amino acid which does not comprise a reactive thiol group, n1 is from 0 to 10, 2 to 8 or 3 to 6, and the two cysteines (C) are covalently joined by a disulphide bridge and a peptide bond.
  • D has the following sequence C-S-S-C(Xi )ni > wherein Xi independently is any amino acid which does not comprise a reactive thiol group, n1 is from 0 to 10, 2 to 8 or 3 to 6, and the two cysteines (C) are covalently joined by a disulphide bridge.
  • L has the following sequence (X 3 )n 3 W(X 4 )n4, wherein X3and X 4 independently are any amino acid which does not comprise a reactive thiol group, W is tryptophan and n3 and n4 each independently are from 1 to 5.
  • LD has the following sequence K(X 5 )n 5 WX 6 CGGGC, wherein X 5 and Xe independently are any amino acid which does not comprise a reactive thiol group, W is tryptophan, K is lysine, n5 is 3, G is glycine and the two cysteine molecules (C) are covalently joined by a disulphide bridge, for example the following sequence KAM- HAWGCGGGC-NH2, wherein CGGGC is cyclic and the two cysteine molecules (C) are covalently joined by a disulphide bridge, K is lysine, A is alanine, M is methionine, H is histidine, W is tryptophan, and G is glycine.
  • LD has the following sequence KAMHAWGC-S-S-CX 7 X 8 -NH2, wherein X 7 and X 8 independently are any amino acid which does not comprise a reactive thiol group, the two cysteine molecules (C) are covalently joined by a disulphide bridge, K is lysine, A is alanine, M is methionine, H is histidine, W is tryptophan, and G is glycine preferably the following sequence KAMHAWGC-S-S-CGG-NH2, wherein the two cysteine molecules are covalently joined by a disulphide bridge, K is Iy- sine, A is alanine, M is methionine, H is histidine, W is tryptophan, and G is glycine.
  • any of X 1 , X 2 , X3, X4, X5, X ⁇ . X7. and Xs are independently any amino acid except cysteine.
  • the amino acid is selected from the group consisting of basic amino ac- ids such as Lys, Arg or His, acidic and amidic amino acids such as Asp, GIu, Asn or GIn, amino acids with non-charged side chains such as GIy, Ala, VaI, Leu, lie, Pro, Ser, Thr, Met, Phe, Tyr or Trp.
  • the amino acid is selected from the group consisting of GIy, Ala, VaI, Leu or Me.
  • the amino acid is selected from the group consisting of GIy, Ala, VaI or Leu, and in a further aspect the amino acid is selected from the group consisting of GIy, Ala or VaI and in still a further aspect the amino acid is selected from the group consisting of GIy or Ala such as GIy.
  • L, D or LD comprises phenylalanine, tyrosine or derivatives of tryptophane, phenylalanine and tyrosine, instead of tryptophane (W).
  • D is as described above and is directly attached to the support, and D comprises one or more aromatic amino acids.
  • L, D or LD does not comprise an aromatic amino acid.
  • a linker comprises an appropriate disulfide bridge, if said disulfide bridge can be activated/broken by an aromatic amino not part of the linker, such as an amino acid provided by the element A the linker L A (L, D or LD) is coupled to.
  • the amino acid is provided by the other element B or by the linker L B (L, D or LD), being part of element B.
  • the amino acid is provided as free amino acid.
  • Figure 2 illustrates an embodiment of the invention and shows an element A, to which a cyclic peptide linker CXWXC is attached, the cysteine joined via a disulphide bridge, which disulphide bridge is disrupted when irradiated to create reactive thiol groups, W is tryptophane (or another aromatic amino acid and X is any amino acid which does not comprise a reactive thiol group, and Y (not to be confused with the single letter code for tyrosine) is part of the linker and/or element A providing attachment of the linker to element A.
  • element B contains a disulphide bridge which is activated to contain reactive thiol groups when element A* (i.e.
  • cysteines may be involved in coupling to the other element; (b) non-cyclic peptide linker KXXXXWXC-S-S-CXX, wherein two cysteines are joined via a disulphide bridge and via a peptide bond; (c) cyclic peptide linker CXWXC, where a part of the linker is a leaving group as both cysteines are only joined via a disulphide bridge; (d) non-cyclic peptide linker C-S-S-CXW, wherein C are cysteines joined via a disulphide bridge and via a peptide bond.
  • cysteines may be involved in coupling to the other ele- ment;
  • non-cyclic peptide linker KXXXXWXCCX where a part of the linker is a leaving group as both cysteines are only joined via a disulphide bridge W is tryptophan, K is lysine, X is any amino acid which does not comprise a reactive thiol group, and Y (not to be confused with the single letter code for tyrosine) is part of the linker providing attachment of the element to which the linker is coupled.
  • the aromatic amino acid 0 is absent; such a linker comprises an appropriate disulfide bridge, if it can be activated/broken by an aromatic amino not part of the linker, such as an amino acid provided by the element A the linker LA is coupled to.
  • the amino acid is provided by the other element B or by the linker L B , being part of element B.
  • the amino acid is provided as free amino acid.
  • the linker comprises an aromatic amino and not a disulfide bridge.
  • the linker provides an appropriate disulfide containing triad, by bringing an aromatic amino acid in the vicinity of an appropriate disulfide bridge, said disulfide bridge being part of either element A, element B or elements A and B.
  • the linker comprises only one amino acid, said amino acid being an aromatic amino acid, or its de- rivative. In an embodiment, s
  • the linker provides a cysteine, capable of forming a disulfide bridge with element A or B, thus providing an appropriate disulfide bridge according to the invention.
  • a linker my also provide the aromatic amino acid necessary for forming a triad.
  • the aromatic amino acid is provided by either element A, element B or both, or as free amino acid.
  • a triad is formed via interaction of to linker.
  • part of the linker may be set free (a leaving group) as a by-product upon disruption of the linker's disulphide bridge.
  • part of the linker may be set free (a leaving group) as a by-product.
  • the by-product (or leaving group) will usually be washed away from the surface if they interfere with subsequent reactions.
  • the free thiol group still part of the linker can participate in the formation of a new disul- phide bond to a free thiol in the polypeptide.
  • the disulphide- containing linker is designed so as to not leave any by-product. Linker - covalent binding
  • a linker as described above is provided to an element through covalent binding of a linker molecule.
  • Many methods are available for the skilled person for making the disulphide-containing linker used in the present invention such as e.g. described in Kimmerlin T.Seebach D. (2004). '100 years of peptide synthesis': ligation methods for peptide and protein synthesis with applications to b-peptide assemblies', J Pept Res, VoI 65, Issue 2, pp. 229-260, McKay, F.C. & Albertson, N.F. (1957) New amine- masking groups for peptide synthesis. J. Am. Chem. Soc. 79, 4686-4690 and Carpino, L.A.
  • Methods for attaching the linker according to the invention to a molecule will be apparent to those skilled in the art and comprise e.g. binding an amine in the peptide linker with an aldehyde via a Schiff-base, cross-linking amine groups in the peptide linker to an amine surface with gluteraldehyde to form peptide bonds, cross-linking carboxylic acid groups present in the peptide linker and molecule to be coupled with carbodiimide, cross-linking based on disulphide bridge formation between two thiol groups and the formation of a thiol-Au bond between a thiol group and a gold surface, preferably the support is aldehyde derivatised silicon or quartz and is attached via a Shifts bond to the lysine amine or the N-terminal amine of lysine.
  • linker-support attachment methods include covalent coupling via e.g. ester bonds, amide bonds, as well as non-covalent coupling such as ionic bonding and hydro- phobic interactions.
  • the linker is provided to an element, support, molecule and/or protein, polypeptide or peptide through covalent binding of a linker molecule, e.g using NHS (N-hydroxysuccinimide), EDC (N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride), activated es- ter, maleimide, disulfide formation, streptavidin/biotin, activated alcohol, vi- nylsulfone, Schiff base formation and/or "click” chemistry and the like.
  • NHS N-hydroxysuccinimide
  • EDC N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride
  • activated es- ter e.
  • the linker is provided via chemical coupling to a protein by NHS, EDC or NHS and EDC chemistry.
  • reaction products will be fractionated and/or purified, in order to remove unwanted reaction products.
  • These can comprise molecules, where more than one linker has been attached to, or where one or more linkers are bound inappropriately with re- spect to the desired coupling reaction according to the invention, or where attachment of the linker impeded desired function and/or activity of the molecule.
  • B-FABP Human Brain Fatty Acid Binding Protein
  • the tertiary structure of the protein constitutes a ⁇ -barrel.
  • This ⁇ barrel consists of 10 antiparallel ⁇ strands making up two almost perpendicular ⁇ sheets. These ⁇ sheets surround a hydrophobic cavity in which the substrate is bound. The cavity is filled with water molecules of which some are released upon substrate binding, resulting in a change in protein intrinsic fluorescence [Reese and Banaszak, 2004].
  • One end of the ⁇ barrel is in some conforma- tions blocked by a helix-turn-helix structure.
  • This structure constitutes a lid which acts as a binding site cavity entrance and exit for the substrate. Opposite to this binding site entrance is both the N- and C-terminus of the protein, and they are both solvent accessible [Chmurzynska, 2006], Figure 4 (Left: Side view. Right: View rotated 90° to the right). There are several solvent ex- posed GIu, Asp, Lys; none of the Trp residues are solvent exposed; one Cys residues is solvent exposed. The structure is obtained from [www.pdb.org, accessed 04-02-06] and the images are generated using PyMOL 0.98.
  • B-FABP is in its native form not expected to be suitable for light induced im- mobilization, as no appropriate disulfide bridge and thus no disulfide bridge- containing triad exists in this protein. It does however contain two unlinked cysteine residues at positions 5 and position 80. One of the two residues is surface exposed and considered reactive towards e.g. thiol activated surfaces. This residue is positioned close to the N- and C-terminus.
  • the protein contains two Trp at position 8 and 97. Trp ⁇ is fully buried while Trp97 is partially buried.
  • B-FABP contains 12 Lys residues and the N-terminus.
  • Also of interest for EDC/NHS chemistry are carboxyl groups.
  • the protein contains 10 Asp residues, 10 GIu residues and the C-terminus. Investigating these residues and termini in terms of solvent accessibility using the Sting Millennium Suite program [mirrors.rscb.org, accessed 05-25-2006] and the PDB file 1 FE3 it can be seen that the protein contain approximately 13 solvent accessible primary amines and 18 solvent accessible carboxyl groups (Figure 4).
  • B-FABP Human Brain Fatty Acid Binding Protein
  • the examples contain the protocols used for the chemical coupling of W6/SS peptide (Table 2), comprising an appropriate disulfide bridge- containing triad with the amino acid sequence KAMHAWGCGGGC to B- FABP and the UV-irraditation-mediated coupling of the W6/SS-B-FABP to a support (thiol-activated quartz surface) via thiol bonds.
  • Table 2 The protocols used for the chemical coupling of W6/SS peptide (Table 2), comprising an appropriate disulfide bridge- containing triad with the amino acid sequence KAMHAWGCGGGC to B- FABP and the UV-irraditation-mediated coupling of the W6/SS-B-FABP to a support (thiol-activated quartz surface) via thiol bonds.
  • a different aspect of the invention relates to the use of techniques involving molecular biology and/or recombinant DNA techniques in order to provide an appropriate disulfide bridge or disulfide bridge-containing triad to a protein.
  • novel, artificial DNA sequence can be created, or existing sequences can be altered or combined.
  • processes such as crossing over technically produce recombinant DNA the term is generally reserved for DNA produced by joining molecules derived from different biological sources.
  • Recombinant DNA techniques can be used to introduce subtle changes in a protein, such as exchange of individual amino acids, point mutations or more substantial changes, such as insertion, deletion or replacement of a string of amino acids, or even fusion of two dif- ferent polypeptides by providing the appropriate changes on the DNA level.
  • completely new DNA and polypeptide sequences can be ere- ated.
  • these molecular techniques can be used to express virtually any desired protein in a wide range of host organisms. The appropriate host or expression organisms and expression systems are known to the artisan.
  • the genes and/or cDNAs in ques- tions are cloned in vectors such as plasmids, and a wide range of commercial vectors are available, including expression vectors for a wide range of organisms.
  • vectors and plasmids the DNA sequences of interest can be inserted into the genome of the desired host organism.
  • the features of the amino acid composition around a spatial disulfide bridge- containing triad (SS0) in a protein which may be used to predict whether it will be susceptible to UV-induced disruption, are as follows: 1 ) an aromatic amino acid residue is located within 15, 12 or 10 A of the disulfide bond; 2) those SS0 in which the angle between the plane of the emitting dipole of the aromatic side chain is orthogonal to the plane of the absorbing dipole of the disulfide bridge are not expected to exchange excitation energy between excited state of the aromatic amino acid and a disulfide bridge.
  • disulphide bridges forming free thiol groups upon irradiation
  • NMR nuclear magnetic resonance
  • X-ray diffraction crystallography analysis In those cases where only a single thiol group is induced by irradiation of tryptophan residues in a protein, as is the case for cutinase, then immobilisation of the protein on a support will occur exclusively via this thiol group.
  • the light-induced method of the present invention leads to targeted disruption of disulphide bridges forming one or only a few accessible thiol groups, whose position can be precisely predicted. The subsequently immobilised proteins will thus have a single or very limited number of orientations.
  • one embodiment of the invention relates to methods of recombinant DNA technology, which are utilized to introduce amino acid substitutions, insertions or deletions into a protein sequence, to create an appropriate disulfide bridge and/or disulfide bridge-containing triad, by e.g. introducing an aromatic amino acid in the vicinity of a disulphide or cysteines capable of forming a disulphide bridge may be introduced in close spatial proximity to an endogenous aromatic residue. Alternatively, an appropriate disulfide bridge and/or disulfide bridge-containing triad may be introduced.
  • Another embodiment of the invention relates to creating a change in the con- formation of a protein through molecular techniques, thereby bringing an aromatic amino acid and an appropriate disulphide bridge in the vicinity of each other.
  • a further embodiment of the invention relates to providing to provide an appropriate disulfide bridge or disulfide bridge-containing triad through amino acid exchanges, insertions, deletions or any combination, re- suiting in an appropriate disulfide bridge or disulfide bridge-containing triad.
  • recombinant DNA technology is used to provide a linker comprising an appropriate disulfide bridge and/or disulfide bridge-containing triad.
  • linker comprising an appropriate disulfide bridge and/or disulfide bridge-containing triad.
  • the disulphide-containing linker is in one aspect of the invention a peptide linker comprising at least one amino acid.
  • the peptide linker comprises at least one aromatic amino acid.
  • B-FABP Human Brain Fatty Acid Binding Protein
  • Figure 6 shows fluorescence emission at 670 nm from a slide onto which SS tagged and labeled B-FABP has been deposited. It is seen that the fluorescence is more intense from small spots of the 5x5 array, which corresponds to the areas illuminated with the 280 nm laser. The fact that emission inten- sity is highest for the areas subjected to UV light indicates that the immobilization is through disulphide bond formation between a Cys residue from a broken disulphide bridge and the thiol activated glass surface. Had the immobilization been through non-covalent interactions (e.g. adsorption), it would have resulted in a uniform immobilization and therefore, a uniform emission from the surface.
  • non-covalent interactions e.g. adsorption
  • cloning strategies C- or N-terminal or internal protein manipulation for enabling light induced immobilization may also comprise: (i) providing a peptide with a disulfide bridge-containing triad; (ii) providing a linker with an appropriate disulfide bridge disulphide bridge, when an aromatic amino acid is provided by the target protein or (iii) providing an aromatic amino acid in the target protein, thereby forming the triad with the appropriate disulfide bridge of the linker.
  • a different embodiment of the invention relates to generating a fusion, comprising a portion of a protein providing the appropriate disulfide bridge or disulfide bridge-containing triad fusion with the target protein to be coupled, which is lacking such an appropriate disulfide bridge or disulfide bridge- containing triad.
  • the peptide or polypeptide must have a free C- or N-terminus, preferably with sufficient spacing to the first cystine residue. Additionally the three dimensional structure of the peptide must be solved to allow three dimensional modeling which may help to determine if the above stated requirements can be achieved.
  • Length of the amino acid sequence preferably below 30.
  • Trp residue Presence of Trp residue. 4. Position of Trp residue, must be within only a few A of at least one di- sulphide bridge, preferably more than one. 5. It these requirements are not met, the following must be considered: a. Presence of mutable amino acid in good position with respect to the disulphide bonds. Preferably Tyr residues because of the resemblance in size with Trp. b. Other needed mutations and the ease by which these can be performed. For example the removal of unwanted Trp residues.
  • Knottin As illustrative of the present invention, a family of peptides was selected which was suitable for this approach, namely the knottin peptides.
  • the family of knottin peptides is a collection of relatively small peptides. This family is characterized by a structural knot facilitated by disulphide bonds. This structure is a special structural motif found in a growing number of peptides. In fact the motif is so widespread that peptides are classified according to the motif although the conservation of the amino acid sequence between them is very low [Craik et al., 2001].
  • Knottins are both found in plants, insects, and animals and are among others utilized as toxins [Craik et al., 2001], [GeIIy et al., 2004]. To make a knot in a peptide there needs to be three disulphide bonds arranged as a ring made by two disulphide bonds with a third disulphide bond penetrating the ring.
  • Cys(l-IV) and Cys(ll-V) form a ring which is penetrated by Cys(lll-VI).
  • the cystines are numbered from the N-terminus to the C-terminus. The image is adapted from [www.knottin.com, accessed 05-12-2006].
  • HpTX2 (PDB: 1EMX) is shown as cartoon with disulphide bonds as lines; the cystines are numbered as in the left image.
  • PDB 1EMX
  • HpTX2 indeed adopts a knotted structure.
  • the primary sequence is seen with disulphide bonds indicated and cystines highlighted.
  • the image has been generated using PyMOL 0.98.
  • the structure of HpTX2 is found at [www.pdb.org, accessed 05-12-2006].
  • knottin peptides A general characteristic of the knottin peptides is their very high stability which is believed to originate from the three disulphide bonds and the knotted topology. In addition the knot is normally very densely packed leading to reduced mobility of the structure hence also increasing the stability [Craik et al., 2001], [GeIIy et al., 2004].
  • the knottin peptides show different possibilities for several therapeutic treatments primarily owing to their toxic nature. Some knottin peptides block sodium channels which make them applicable for pain therapy while others are potential antibacterials because of antimicrobial properties. Most important in this context is their potential for use as scaffolds in protein engineering. This utilizes the great stability of knottin peptides because substantial changes can be introduced in the loop regions of the pep- tide giving it new properties without destroying the stability [Craik et al., 2001].
  • Examples 10-14 illustrate the development of a mutant knottin peptide (HpTX2) for recombinant fusion to proteins lacking an appropriate disulfide bridge or disulfide bridge-containg triad.
  • HpTX2 mutant knottin peptide
  • a universal expression vector was designed and produced for fusion of an engineered, cystine-rich (S-S rich) peptide, based on the knottin fold HpTX2, to the C terminus of virtually any protein devoid of an appropriate disulfide bridge or disulfide bridge, like B- FABP.
  • a further aspect relates to a vector or plasmid providing an appropriate disulfide bridge or catalytic triad fused to the N- or C-terminus of a protein to be expressed by said vector or plasmid in an appropriate host.
  • Another aspect relates to a vector or plasmid that provides an appropriate disulfide bridge or catalytic triad by fusion of a protein by C- or N-terminal fusion to a protein or part thereof or a natural or synthetic polypeptide or peptide.
  • a useful linker peptide is knottin (HpTX2).
  • Examples 13-14 demonstrate the feasibility of a universal expression vector, such that a linker peptide, which contains the UV reactive triad in form of a disulfide bridge-containing triad and any protein are trans- lated during protein synthesis as one fusion protein.
  • coupling of two elements may be provided by adding a free aromatic amino acid, either alone or being part of a molecule, to the vicinity of one or more appropriate disulfide bridges-
  • free amino acid is provided in solution.
  • the invention is not limited to a single, free aromatic amino acid but may also comprise a mixture of two or more different aromatic amino acids.
  • the free aromatic amino acid is part of a molecule.
  • more than one aromatic amino acid or their analogues or derivates with comparable excitation and emission profiles are provided being part of one or more molecules, not attached to either element A or B.
  • the irradiation step according to the invention comprises light of a wavelength that excites one or more aromatic amino acids. This may be achieved using UV light, such as UV light in the wavelength interval of 250 to 305 nm, or with light having longer wavelengths that by means of non-linear processes and/or multiphoton excitation promotes the same electronic transitions as light in said wavelength interval of 250 to 305 nm.
  • the wavelength interval is preferably 250 to 260nm, 270 to 280 nm or 290 to 300nm, and more preferably about 254, 275 or 295 nm.
  • a combination of different wavelengths may be applied, which may comprise the above mentioned intervals.
  • the irradiation is preferably performed with a light source of a wavelength of between about 250 nm and about 320 nm, more preferred between about 275 nm and about 300 nm, or IR/visible light for multi-photon excitation.
  • the irradiation step comprises light of a wavelength that specifically excites one or more aromatic amino acids, or other molecular system that may mimic aromatic amino acids, preferably light of a wavelength that excites one specific aromatic amino acid such as e.g. the wavelength of approximately e.g.
  • the polypeptide is irradiated in the presence of a free aromatic amino acid, such as Trp, Tyr and Phe.
  • Irradiation with 295 nm light permits the selective excitation of tryptophan residues in a protein, which in turn may lead to the disruption of a single or a limited number of disulphide bonds.
  • a variety of light sources suitable for the irradiation of proteins at a range of wavelengths, for the photo-induction of disulphide bond disruption include, but are not limited to, a 75-W Xenon arc lamp from a research grade spectrometer such as a RTC PTI spectrometer, a deuterium lamp, a high pressure mercury lamp.
  • Irradiation at a single wavelength can be obtained by coupling the light source to a monochroma- tor.
  • a source of single and multiple photon excitation includes a high peak- power pulsed or CW laser.
  • Prolonged selective excitation of tryptophan residues in a polypeptide such as a protein will only lead to disruption of those disulphide bridges to which excitation energy is transferred.
  • illumination time is around 1 msec, 10 msec, 100 msec, 1 sec, 5 sec, 10 sec, 30 sec, 1 min, 5 min or more.
  • An aspect of the invention provides a coupling between elements, resulting in an immobilization on a support or surface, which can be spatially controlled.
  • a support and/or surface may also be a derivatized support that is capable of binding a thiol group, such as a support and/or surface comprising a thiol group or a disulfide bridge.
  • a surface or support may comprise a spacer.
  • This method of light induced thiol coupling can also be used to immobilise a protein on a support.
  • the most common types of bonds that are formed during coupling to a support are disulfide bonds and sulfur-metal bonds (primarily sulfur-gold) where a self-assembled layer is formed. As both types of bonds are stable, extensive washing after immobilization will not displace the protein.
  • the support comprises a spacer.
  • a spacer may be represented in the form of "Y".
  • the spacer is covalently bound to the support.
  • the spacer is a part of the linker molecule to be coupled according to the invention.
  • the spacer improves the coupling reaction according to the invention.
  • the support to which a molecule is coupled according to the invention may be any biological, non-biological, organic, inorganic or a combination of any of these materials existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, slides, etc. It can have any convenient size and shape.
  • the support is insoluble.
  • the support comprises a material selected from the group consisting of polymer such as polystyrene, polyethylene, polyester, polyethermide, polypropylene, polycarbonate, polysulfone, polymethylmethacrylate, or poly(vinylidene fluoride), and silicon or quartz.
  • polymer such as polystyrene, polyethylene, polyester, polyethermide, polypropylene, polycarbonate, polysulfone, polymethylmethacrylate, or poly(vinylidene fluoride), and silicon or quartz.
  • the support is selected from the group consisting of an electronic chip, slide, wafer, resin, well, tube, micro array and membrane.
  • the support comprises a material selected from the group consisting of polystyrene, polyethylene, polyester, polyethermide, polypropylene, polycarbonate, polysulfone, polymethylmethacrylate, poly(vinylidene fluoride), and silicon.
  • the insoluble support may be coated with a layer of the disulphide-containing linker.
  • the polypeptide coupled to the support is selected from the group consisting of an enzyme such as selected from the group consisting of cutinase, chymosin, glucose oxidase, lipase, Iy- sozyme, alkaline phosphatase and plasminogen, transcription factor, protein domain, binding protein, antigen and immunoglobulin, such as a F(ab) fragment.
  • an enzyme such as selected from the group consisting of cutinase, chymosin, glucose oxidase, lipase, Iy- sozyme, alkaline phosphatase and plasminogen, transcription factor, protein domain, binding protein, antigen and immunoglobulin, such as a F(ab) fragment.
  • the invention relates to an insoluble coupled support comprising one or more polypeptide(s) coupled by the method according to the invention or another method.
  • the coupled polypeptide may suitably be specifically oriented.
  • the coupled support according to the invention comprises a material, such as one selected from the group consisting of an electronic chip, slide, wafer, resin, well, tube, micro array and membrane and the material of the support may be selected from but is not limited to the above group consisting of polystyrene, polyethylene, polyester, polyethermide, polypropylene, polycarbonate, polysulfone, polymethylmethacrylate, poly(vinylidene fluoride), and silicon.
  • the polypeptide coupled to the support is preferably spatially controlled.
  • the coupled support is used in a bio- functional reaction such as a bio-sensor, chromatography, immunodetection, enzyme assay, nucleotide binding detection, protein-protein interaction, protein modification, support targeting and protein targeting.
  • a bio- functional reaction such as a bio-sensor, chromatography, immunodetection, enzyme assay, nucleotide binding detection, protein-protein interaction, protein modification, support targeting and protein targeting.
  • the coupled support may also be used in a diagnostic or biosensor kit.
  • the use of the method according to the in- vention for the production of polypeptide-based surface coating is provided, in particular for use in the production of polypeptide-based biosensors, polypeptide-based micro arrays, and food packing materials with polypeptide- based surface coatings e.g. for the production of anti-microbial food packing materials.
  • the method according to the invention of light induced thiol coupling can also be used to immobilise a protein on a support. The disulphide bond between the linker and the protein is stable, and extensive washing after immobilisation will not displace the protein.
  • the density of proteins on a support can be controlled by varying the protein concentration, or the intensity and duration of UV-irradiation, and subsequently blocking the remaining activated thiol groups on the surface with reagents such as L-cysteine, (2-(2- pyridinyldithio)ethaneamine hydrochloride (PDEA) or with a thiol-lipid bilayer (Hong Q., et. al., 2001 , Biochemical Society Transactions 29(4):587-582).
  • PDEA 2-(2- pyridinyldithio)ethaneamine hydrochloride
  • the support, with evenly distributed immobilised proteins, is therefore blocked to prevent non-specific binding.
  • the method of immobilisation does not involve any chemical steps, since the thiol-activated proteins formed by UV radiation, spontaneously self-assemble on the support.
  • the described thiol and disulphide exchange reactions are an effective and rapid way to bind molecules to supports.
  • Immobilisation of a polypeptide on a support can also be spatially controlled.
  • Present day laser technology allow for focal spots with dimensions of 1 micrometer or less. If a specific polypeptide or target molecule, containing SS bridge(s), is incubated with the disulphide-containing support the light- induced thiol group formation and coupling could be limited to the focal points of illumination. This approach would allow for an extremely dense packing of identifiable and different molecules on a support surface. Thus, the method of the present invention could be used for charging micro arrays with molecules.
  • One different aspect of the invention relates to generation of dimmers, oligomers, polymers and/or dendrimers.
  • This method of coupling of two elements according to invention can be used to construct various types of disul- phide-linked oligomers or polymers.
  • Light-induced thiol groups in a given protein or peptide or other biomolecules can be coupled to a support. Provided that the concentration of protein and support molecules in the coupling reaction is sufficiently high, SS based cross-linking between neighbouring molecules will take place. While the light-induced protein or molecule should contain an SS bridge, the possession of an aromatic residue as close spatial neighbour is not essential, since the aromatic contribution to the reaction may be supplied by aromatics amino acids or their derivatives, added to the coupling reaction.
  • Dimers Another aspect relates to dimers, such as homo- or heterodimers, consisting of two identical or different elements or subunits. Upon coupling of two elements according to the invention, a dimer is formed.
  • Another embodiment relates to dimers, homo or hetero, where one or more appropriate disulfide bridges and/or one or more additional triads can be activated by different irradiation wavelengths than the first appropriate disulfide bridge or triad.
  • a further embodiment concerns the formation of heterodimers, were the formation of (undesired) homodimers is reduced or avoided. This can be achieved by designing the elements/units in such a way, that e.g. one unit provides one (or more) aromatic amino acids, and the other one the appropriated disulfide bridge, thus preventing the formation of homodimers.
  • dendrimers such as homo- or hetero den- drimers.
  • These tree-like, or generational structures can be synthesized using the coupling according to the invention, using identical or different units, elements or building blocks according to the invention.
  • Dendrimers can be used in drug delivery (Sezen Gurdag et al., 2006). There are two defined methods of dendrimer synthesis, divergent synthesis and convergent synthesis. The former assembles the molecule from the core to the periphery and the latter from the outside to termination at the core. Both methods are possible using the coupling method according to the present invention.
  • Figure 9 shows examples of different embodiments of the invention regarding dendrimer units/elements before coupling (SS0 x> SS0 y , SS0 z : identical or different triads used for coupling; L 3 , U, L 0 : identical or different linkers): (a) Dendrimer unit with three identical or different triads (SS0 X , SS0 y , SS0 z ) located on one or more identical or different internal linkers; additional, internal triads, not intended for coupling (SS ⁇ j) may be present; (b) Dendrimer unit before coupling comprising an internal triad SS0 x intended for coupling; SS0y and SS0 z are located on identical or different linkers; additional, identical or different internal triads not intended for coupling may be present (not shown)); (c) Dendrimer unit comprising two internal triads (SS0 x and SS0 y ) intended for coupling; SS0
  • the coupled support according to the invention may suitably be used for drug delivery.
  • the polypeptide is in one aspect of the invention selected from the group consisting of an enzyme such as selected from the group consisting of cutinase, chymosin, glucose oxidase, lipase, lysozyme, alkaline phosphatase and plasminogen, a transcription factor, a protein domain, a binding protein, an antigen and an immunoglobulin, such as a F(ab) fragment.
  • a method of delivering a drug or prodrug to a patient comprising: (i) providing a support coupled to one or more polypeptides, (ii) administering the support-coupled polypeptide to a patient, (iii) irradiating the support-coupled polypeptide to create a thiol group in the molecule by disulphide bridge disruption, and thereby releasing the polypeptide from the support.
  • the support in itself may be a pharmaceutical drug and in another aspect of the invention, the coupled polypeptide is a drug or a prodrug.
  • This method of light-induced coupling to a support can be usefully applied to other types of support molecule, such as pharmaceutical drugs, in order to facilitate their effective delivery.
  • a water-soluble molecule containing a disulphide bridge including but not lim- ited to a peptide or protein
  • the molecule coupled to the drug may serve to protect the drug from its physiological environment, and hence improve its stability in vivo. This particular feature makes this technology attractive for the delivery of labile drugs such as proteins.
  • Support-linked prodrugs are generally defined as prodrugs that contain a temporary linkage of a given active substance to a transient support group that produces improved physicochemical or pharmacokinetic properties and that can be easily removed in vivo, usually by a hydrolytic cleavage.
  • light-mediated disruption of the disulphide bond linking a drug to a molecule can be used to achieve a controlled release of the active drug from the molecule-coupled form, implanted in the patient. This would minimise the frequency of drug delivery to the patient, and provide for light- controlled dosing.
  • the process of drug delivery may be optimised, by only illuminating those regions of the body where drug release is necessary. These features would improve patient compliance, especially for drugs used for chronic indications, requiring frequent injections (such as for deficiency of certain proteins or metabolites). Controlled drug release could be induced by infra-red light (via two-photon excitation) in the case of transdermal drug delivery, within the penetration range of infra-red light, while the greater penetration of UV light (or infra-red light via three-photon excitation) would facilitate drug release deeper within the patient. Also, the use of optical fibers allows the delivery of light at various depths in the body, as used in PDT (photodynamic therapy), as for example in the treatment of cancer/tumor patients.
  • PDT photodynamic therapy
  • the support comprises a (nano)particle or a magnetic (nano)particle (see below for further embodi- ments regarding magnetic (nano)particles).
  • the senor comprises fiber optics, to which molecules, such as biomolecules are coupled to the area or surface of point of entry or exit of light, either directly or via a spacer or another support.
  • This method and/or device may be used to detect changes of light based on interaction of the sensor with its environment, comprising luminescence, light scattering, absorbance, reflection, transflection, fluorescence and/or light quenching reactions, or any combination of the above.
  • Another embodiment of the invention relates to a method or device comprising a sensor for monitoring interactions between molecules, said device comprising elements coupled according to the invention.
  • a further embodiment relates to cantilever for atomic force microscopy. It is known in the field that the correct orientation of the molecules coupled to the tip of such a cantilever is crucial in order to obtain more accurate and precise measurements, and/or an improved signal to noise ratio. This desired, correct orientation of the molecules can be provided by the invention.
  • a further aspect of the present invention relates to a cantilever for atomic force microscopy, where the cantilever comprises a molecule coupled by irradiation of a disulfide bridge or disulfide containing triad.
  • the bond immobilising the protein to the support may be disrupted, releasing the protein into solution.
  • Disul- phide bridges between a protein and the support can be disrupted e.g. with UV irradiation, in the same way as disrupting a disulphide bond on a protein, where an aromatic amino acid is a spatial neighbour.
  • the aromatic amino acid can either be located on the immobilised protein itself, or be supplied in the form of a solution of an aromatic amino acid, such as tryptophan, applied to the support surface.
  • Disulphide bonds (SS) themselves are known to be disrupted by approximately 254 nm light.
  • disulphide bridges be- tween a protein and a support can be disrupted with (dithiothreitol) DTT, or other reducing agents known to persons skilled in the art. Following disruption of the immobilisation bond, the released protein can be purified, if necessary, and used in further experiments.
  • a further aspect of the present invention is regenerating a gold surface by removing proteins that are immobilised through a thiol-Au bond with O 2 - plasma treatment or Piranha, thereby removing the top layer of the gold surface including the proteins.
  • a coupled molecule or polypeptide may be released from the support by irradiating the molecule or polypeptide to create a thiol group in the polypeptide by disulphide bridge disruption.
  • the wavelengths used for immobilization and release are different.
  • the release is provided by another disulfide bridge-containing triad.
  • the release is provided by triggered by providing a free amino acid to the disulfide bridge formed during coupling.
  • Magnetic (nano)particles Magnetic particles can be coupled with elements, such as molecules, polypeptides, drugs, prodrugs, biomolecules or the like, according to the inven- tion.
  • the particles se can vary in size and shape, and may even be as small as nanoparticles.
  • magnetic (nano)particles are used in the concentration, extraction, removal or purification of substances, such as recovering enzymes, toxic-, fluorescent or radioactive compounds.
  • a further embodiment relates to a magnetic (nano)particle, where the magnetic (nano)particles comprises a (bio)molecule coupled by irradiation of a disulfide bridge or disulfide containing triad.
  • magnetic (nano)particles are used in the treatment of a patient, human or animal, where one or more biologically active substances are concentrated in the area of treatment, by providing an appropriate magnetic field. Thereby the activity is increased at the area of activity and/or other parts of the organism are protected against it.
  • the magnetic (nano)particles comprising bio- molecules coupled according to the invention are used in cancer treatment, such as chemotherapy or radiation treatment.
  • an active portion of the biologically active substance is released upon irraditation according to the invention.
  • the magnetic (nano)particles comprise den- drimers coupled according to the invention.
  • one or more biologically active substances are removed from the patient by the use of magnetic nanoparticles and providing an appropriate magnetic field.
  • the magnetic (nano)particles according to the invention are used in combination with a fluorescent label or radioactive compound.
  • the magnetic (nano)particles according to the invention are used in combination with a substance, molecule, biomolecule, polypeptide and the like, that can be recycled, i.e. that retains a significant or considerable portion of its activity after use, and thus maintains its capability of being reused, either in its form after use or after reactivation or modification.
  • radioactive magnetic (nano)particles can also be used to remove (radioactive) markers from a tube system, such as water pipes in a heating system, in combination or after search for leaks.
  • the total dosage of molecules, polypeptides or biomolecules can be reduced by the use of magnetic (nano)particles.
  • FIG 27 schematically illustrates a more detailed specific aspect of material deposition by light induced molecular immobilization. Shown is a light source (102) in the form of a laser. Such a method and/or device may be useful for providing bioarrays. Examples of one embodiment of a bioarray are given in Figures 5 and 6:
  • the bioarray is coupled with molecules and/or biomelecules according to the invention, such as protein, peptide, polypeptide, DNA, RNA and the like, either in natural, derivatized, modified, engineered or synthetic form, or in combination.
  • Such molecules may also comprise a combination of different elements, such as molecules or supports, which may also be coupled according to the invention.
  • the laser is a solid state diode-pumped mode-locked titanium-Sapphire (Ti-Sapphire) laser delivering e.g. 0.9 W of 840 nm near- infrared and approximately 80 femtosecond long laser pulses at a repetition rate of 80 MHz.
  • Ti-Sapphire titanium-Sapphire
  • One example of such a laser is e.g. the Tsunami 3960 laser by Spectra Physics, Mountain View, CA.
  • the laser may e.g. be pumped by a high power (5W at 532 nm) solid state laser such as Millennia V by Spectra Physics.
  • the laser pulses are passed through a pulse picker (110) reducing the repetition rate to 8 MHz before entering a doub- ler/tripler unit (111) (e.g. GWU from Spectra Physics) where the reduced laser pulses are used to generate the third harmonic of 840 nm to yield ap- proximately 1 mW of approximately 200 femtosecond long 280nm UV pulses at 8 MHz.
  • the pulse picker (110) is not necessary for immobilization but gives a simple way of controlling the power of the light.
  • the resulting UV pulse train is then passed to (e.g. using mirrors, optical fi- bres and/or components, and/or the like (113)) a light exposure controlling system (104) comprising in this particular embodiment a shutter (112), being controlled by the controller (101), receiving the UV pulse train and passing the UV pulse train through (when the shutter is controlled to be open) to a beam expander (114) (or an optical lens) expanding the beam, an iris dia- phragm (115) and a finally a focusing lens (116) focusing the beam into a spot (or an area) of an appropriate size (e.g. about 25 micrometers but via an appropriate light source (102) and/or light exposure controlling system (104) even down to 1 micrometer and below in the nanometer range).
  • a light exposure controlling system (104) comprising in this particular embodiment a shutter (112), being controlled by the controller (101), receiving the UV pulse train and passing the UV pulse train through (when the shutter is controlled to be open) to a beam expander (114) (or
  • the shutter is not needed for embodiments using a mask, a template, a micro-lens array and/or by the use of a so-called digital micro- mirror device (DMD), etc. where the object or a larger portion (than a spot) of the object is illuminated by the light source.
  • DMD digital micro- mirror device
  • the object (103) comprising molecules to be immobilized is, in this particular embodiment, mounted on a 2D or 3D translation stage (117) (controlled by controller (101)) with the surface of the object comprising molecules to be immobilized in substantially the focal plane (at least when light is to immobilize the molecules on the object (103)) of the UV-light).
  • the translation stage may also be used to bring the surface out of focus, i.e. bring the object out of the focal plane, e.g. if an immobilization pattern is to be produced due utilizing diffraction. Additional aspects are given in the co- pending application by the same applicant filed on the same day.
  • B-FABP human brain fatty acid binding protein
  • B-FABP human Brain Fatty Acid Binding Protein
  • Wild-type B-FABP was expressed in Escherichia coli (E.coli) BL21(DE3).
  • Tagged B-FABP with S-S containing peptides was expressed in Escherichia coli (E.coli) Origami(DE3).
  • B-FABP was expressed in inclusion bodies using following protocol: A preculture of 3 ml LB medium with a selected colony is grown overnight with an appropriate antibiotic, Ampicillin 100 (100 ⁇ g/ml) or Carbenicillin 50 (50 ⁇ g/ ⁇ l). 500 ml of enriched medium e.g. SOB medium with Amp 100 or Carb 50 is prepared, and the preculture was added. The cell culture is grown to an OD of 0.6, after which 200 ⁇ M of IPTG is added. The cell culture is allowed to induce over night at 30 0 C under continuous stirring.
  • the induced cell culture is then centrifuged at 5000 rcf for 30 minutes at 4°C, and the supernatant is discarded.
  • the cell pellet is then re- suspended in 100 ml TES buffer and 10 ml of lysis buffer (lysozyme 1mg/ml in TES buffer) is added. The mix is kept on ice for 30 minutes to allow for cell lysis, and frozen before further processing. After thawing, 20 ml of detergent buffer is added to the lysate, which is then centrifuged at 5000 rcf for 10 minutes.
  • the pellet is washed 3 times with 20 ml 1 % Triton X100 and 3 times with 20 ml of MiIIi-Q H 2 O during each wash the sample is centrifuged at 5000 rcf for 10 minutes, and finally resuspended in 100 ml of MiIIi-Q H 2 O.
  • the lysate is pulse sonicated with 500,000 J for 5 minutes (30 sec pulse, 30 sec wait), and centrifuged at 5000 rcf for 10 minutes at 4°C. The sedimented pellet was recovered and frozen for further use.
  • the pellet containing B-FABP inclusion bodies was dissolved in a 10 ml pH 7.5 solution containing 8 M urea, 1 mM DTT, and 10 mM Tris. This solution was stirred using a magnetic stir bar for 15 minutes. Following 1 ⁇ l was taken out for subsequent concentration determination through OD measurements. The remaining solution was then diluted to 1.5 M urea using a pH 7.5 solution consisting of 1 M arginine, 1 mM DTT, and 10 mM Tris reaching a B-FABP concentration of approximately 0.1 mg/ml. After diluting the solution was stirred intensively for 10 minutes at 4 0 C. Subsequently the solution was dial- ysed in 10 mM Tris pH 7.5 for 24 hours with gentle stirring.
  • the salt concentration affecting the ionic strength / conductivity and thereby the binding affinity of the protein to the column matrix are given.
  • the secondary y-axis is the proportion of buffer B in the eluent (in %, v/v). From OmI to 110ml the column is flushed with buffer A. From 110ml to 140ml buffer B is raised to 10%. At 130ml of elution, the protein is released from the column, as seen by a peak of absorbance at 133ml. The sample fraction from 130ml to 136ml is expected to hold the highest concentration of protein and is collected (indicated by red triangles). From 140ml the salt concentration is rapidly raised to 100% releasing the remaining contaminant proteins from the column. From 150ml to 170ml smaller peaks in the blue and purple curves show that some excess protein is released.
  • Tris(hvdroxvmethyl)aminomethane (C4H11 NO3), Cas: 77- 86-1 , AppliChem; Sodium chloride (NaCI), Cas: 7647-14-5, JT. Baker; Folded B-FABP sample;Amersham Biosciences Akta Purifier controlled by Unicorn 5.01 software; HiTrap Q HP anion column.
  • this buffer was exchanged with MES buffer before chemical coupling between the Tag peptide and B-FABP.
  • the B-FABP solution was transferred to dialysis bags. These were placed in a 50 mM MES buffer pH 5.8 at room temperature under stirring. After 3 hours the MES buffer was replaced by a fresh solution and the dialysis was continued over night.
  • the concentration of B-FABP after dialysis was determined by OD measurements at 280nm, assuming a molar extinction coefficient of 13940 M '1 cm "1 .
  • the coding sequence for human B-FABP was PCR-amplified with the follow- ing forward and reverse primers, LD007fw and LD039rv (Table 2), respectively.
  • the reverse primer was designed to create an in-frame C-terminal fusion of the peptide sequence PGCGGGC to the coding sequence of B-FABP.
  • the PCR amplicon was cloned into the ⁇ /ctel and SamHI restriction sites of the pET11a plasmid (Novagen). Optimization of the annealing temperature for the hybridisation and extension PCR using the primers LD007fw and
  • LD039rv coding for the SS tag and the B-FABP template strand can be seen in Figure 11.
  • the wells were loaded with increasing temperature from left to right (45 0 C to 65 0 C), the agarose gel was 1.5%, and the ladder step size was 100 bp. For all samples a clear band is seen at 450 bp as expected. The in- tensity of the bands was found to increase with increasing annealing temperature.
  • the DNA samples were analyzed on agarose gels. DNA was then cleaned using a PCR cleaning prep kit and the concentration was determined by OD measurements.
  • a double digest was conducted with 40 ⁇ l SS tagged B-FABP DNA (100 ng/ul), 0.5 ⁇ l Nde ⁇ , 1 ⁇ l SamHI, 20 ⁇ l Y /Tango buffer and 39 ⁇ l of sterile MiIIi-Q H2O overnight.
  • the digestion product was cleaned using the phenol-chloroform extraction and the end product verified on a 1.5 % agarose gel and concentration determined by OD measurements.
  • ligation 7 ⁇ l of SS tagged B-FABP (100 ng/ ⁇ l) insert was mixed with 2 ⁇ l of pET-11a (600 ng/ ⁇ l), 2 ⁇ l of ligation buffer, 2 ⁇ l of T4 ligase, and 6 ⁇ l of MiIIi-Q H2O.
  • the ligated plasmid was transformed into competent E. coli DH5 ⁇ cells, and plated onto LB-Amp 100 plates. After incubation over night at 37°C, 20 colonies were picked and replated onto a new LB-Amp 100 plate and left at 37°C over night.
  • the replated colonies were subjected to a screening PCR with primers T7fw and T7rv and analyzed on 1.5% agarose gels (see Figure 12 ; lanes 1 , 2, 3, 5 and 6 holds the colonies 14, 15, 16, 17, and 18, respectively, while a 100 bp ladder is in well 4). Bands were seen at 550 bp for the colonies 14, 15, 16 and 18 as expected, while a 950 bp band was seen for colony 17. The ladder size is 100bp and the gel is a 1.5% agarose gel. Based on visual confirmation from the gel analysis, colonies were picked and transferred into 3 ml of LB medium with Amp 100 , and left over night.
  • a screening PCR was conducted with T7fw primer and T7rv primer. After incubation 1 ml of preculture was ex- tracted and 100 ⁇ l of glycerol was added to cryo preserve the sample before it was frozen at -85°C. The additional 2 ml of culture were purified using a Quiagen plasmid mini prep kit. The purified plasmid was suspended in 100 ⁇ l of elution buffer. The plasmid containing the cloned SS tagged B-FABP was then transferred into E.
  • coli Origami (DE3) cells for expression (see Example 1 for details regarding expression and purification). 6 colonies were picked onto a new Amp 100 plate. A test expression was conducted by washing the Amp 100 plate with 4 ml of LB medium. 3 ml of washed bacteria culture was extracted to an inoculation tube along with 6 ⁇ l of Amp 100 and 12 ⁇ l/ml IPTG. The tube was left at 37°C for 3 hours, and then placed at 4°C. To express the modified B-FABP with linker, 500ml SOB medium with Amp 100 was grown with the selected colony to an OD of 0.6, after which 12 ⁇ l/ml of IPTG was induced, and the cell culture was allowed to induce over night at 30 0 C under continuous stirring.
  • the weight of the inclusion body pellet was 56 mg. 14 mg of the pellet was extracted and resuspended in 0.5ml Urea 8M. The 14 mg protein was purified and refolded according to the re- folding protocol (Example 1 ).
  • PCR primers LD007fw; LD039rv; T7fw and T7rv, TAGCopenha- gen (see Table 2); Nde ⁇ restriction enzyme, 20u/ ⁇ l, New England BioLabs; SamHI restriction enzyme, 10u/ ⁇ l, Fermentas; Buffer Y /Tango with BSA 10x, MBI-Fermentas; pET-11a vector DNA, Novagen; T4 DNA ligase, Roche Diagnostics GmbH; Ligation buffer 10x, Roche Diagnostics GmbH; LB medium with Amp ; Glycerol 99% (C3H8O3), Cas: 56-81-5, Sigma; E.
  • FIG. 13 shows 15%a SDS-PAGE gel holding SS tagged B-FABP in lane 2 with W6/SS Cross linked BFABP in lane 3 and native B-FABP in lane 4.
  • the marker in lanes 1 and 5 is MBI marker SM0671.
  • the band height for SS tagged B-FABP and W6/SS Cross linked B- FABP appears slightly higher than for native B-FABP. All three bands are found below the 15 kDa marker, which is in good agreement with the fact that the tagged protein bears additional amino acids.
  • SSFS Steady State Fluorescence Spectroscopy
  • Static scatter spectras were recorded from 450 nm to 550 nm at 11.5 0 C with excitation at 500 nm. In both emission specters and static scatter specters 5 accumulations were acquired and the integration was 0.1 second per point. Thermal scans were recorded at 350nm from 11.5°C to 82°C and again from 82°C to 11.5 0 C with excitation at 292 nm and a temperature step size of 1.5 0 C per minute and 1 point per second. All SSFS measurements were averaged by a smoothing function in FeliX32.
  • Figure 14 shows measurements of 300 - 400 nm emission from native and W6/SS Cross linked B-FABP prior to heating using (SSFS). Excitation was done at 292 nm. The pH was 5.86 and the temperature was 11.5 0 C for both samples. The ratio of 330/350 nm emission is respectively seen to be 1.47 and 1.37. Finally it is noticed that the emission intensity of the W6/SS Cross linked B-FABP is higher than that of the native B-FABP. The curves were generated using a smooth function in FeliX32 software.
  • Figure 15 shows measurements of 300 to 400 nm emission from W6/SS Cross linked B-FABP before heating and after heating to 82°C and subsequent cooling to 11.5 0 C using SSFS. Excitation was at done 292 nm. The pH was 5.86 and the temperature was 11.5 0 C for both samples. It is seen that the ratio of 330/350 nm emission decreases from 1.37 to 1.22. This indicates that the Trp residues become exposed to a more polar environment.
  • Figure 16 displays the result of a thermo scan conducted on native and one conducted on W6/SS Cross linked B-FABP. Excitation was done at 292 nm whereas emission was collected at 350 nm. The pH was 5.86 for both samples. It is seen that the curvature of the two curves are similar. The transition mid point for both samples is approximately 55°C, indicating that the two proteins bear the same conformation. As with the emission scans it is noticed that the emission intensity of the W6/SS Cross linked B-FABP is higher than that of native B-FABP.
  • Emission scans of SS tagged B-FABP and native B-FABP were conducted in order to compare the tryptophan distribution, see Figure 17.
  • the emission scans were recorded from 300-400 nm upon 292 nm excitation.
  • the curves were processed using a smooth function in FeliX32 software. It is seen that emission at 350 nm is higher for SS tagged B-FABP than for native B-FABP, while the two have equal amounts of 330 nm emission.
  • the ratio of 330/350 nm for SS tagged B-FABP before heating is 1.243, compared to 1.469 for native B-FABP. This indicate that tryptophans are in a more polar environment in SS tagged B-FABP than in native B-FABP.
  • the times at which the different substances were added can be seen in Table 3.
  • the TIRF apparatus settings were: Gain: 4.7 V, Signal: 3.9 V, Excitation wavelength: 285 nm, Emission wavelength: 340 nm, Pump speed: 4.16 ⁇ l/s.
  • Figure 14 shows measurements of 300 - 400 nm emission from native and W6/SS Cross linked B-FABP prior to heating using (SSFS). Excitation was done at 292 nm. The pH was 5.86 and the temperature was 11.5 0 C for both samples. The ratio of 330/350 nm emission is respectively seen to be 1.47 and 1.37. Finally it is noticed that the emission intensity of the W6/SS Cross linked B-FABP is higher than that of the native B-FABP. The curves were generated using a smooth function in FeliX32 software.
  • Figure 15 shows measurements of 300 to 400 nm emission from W6/SS Cross linked B-FABP before heating and after heating to 82°C and subsequent cooling to 11.5 0 C using SSFS. Excitation was at done 292 nm. The pH was 5.86 and the temperature was 11.5 0 C for both samples. It is seen that the ratio of 330/350 nm emission decreases from 1.37 to 1.22. This indicates 71
  • Trp residues become exposed to a more polar environment.
  • Figure 16 displays the result of a thermo scan conducted on native and one conducted on W6/SS Cross linked B-FABP. Excitation was done at 292 nm whereas emission was collected at 350 nm. The pH was 5.86 for both samples. It is seen that the curvature of the two curves are similar. The transition mid point for both samples is approximately 55°C, indicating that the two proteins bear the same conformation. As with the emission scans it is noticed that the emission intensity of the W6/SS Cross linked B-FABP is higher than that of native B-FABP.
  • Emission scans of SS tagged B-FABP and native B-FABP were conducted in order to compare the tryptophan distribution, see Figure 17.
  • the emission scans were recorded from 300-400 nm upon 292 nm excitation.
  • the curves were processed using a smooth function in FeliX32 software. It is seen that emission at 350 nm is higher for SS tagged B-FABP than for native B-FABP, while the two have equal amounts of 330 nm emission.
  • the ratio of 330/350 nm for SS tagged B-FABP before heating is 1.243, compared to 1.469 for native B-FABP. This indicate that tryptophans are in a more polar environment in SS tagged B-FABP than in native B-FABP.
  • the times at which the different substances were added can be seen in Table 3.
  • the TIRF apparatus settings were: Gain: 4.7 V, Signal: 3.9 V, Excitation wavelength: 285 nm, Emission wavelength: 340 nm, Pump speed: 4.16 ⁇ l/s.
  • Figure 20 displays static light scattering measurements of W6/SS Cross linked B-FABP before and after heating using total internal reflection fluorescence (TIRF) analysis.
  • the pH was 5.86 and the temperature was 115 0 C for both samples. It is seen that heating and subsequent cooling of the sample leads to a nearly 9 fold increase in static light scattering by W6/SS Cross linked BFABP.
  • the emission peak before heating compared to the wavelength of excitation is red shifted 1 nm. After heating the emission peak is red shifted 0.5 nm compared to wavelength of excita- tion.
  • Table 3 The time of injection and time of flushing for the substances used during TIRF experiment.
  • the principle of Ellman's reagent (5,5'-dithio-bis(2-nitrobenzoic acid)) (DTNB), is that it reacts with free and solvent exposed thiol groups to form mixed disulfides, i.e. it leads to the release of a free chromogenic 5-thio-2- nitrobenzoic acid (TNB) moiety, whereas the other half of DTNB reacts with one free thiol (R-SH) to form a non chromogenic mixed disulfide.
  • TNB 5-thio-2- nitrobenzoic acid
  • R-SH free thiol
  • the quantification of free thiol groups is done by measuring absorbance on the sample. Specifically measurements are conducted on TNB which has an extinction coefficient of 14150 M "1 cm "1 at 412 nm.
  • Table 5 displays the measured absorbance values of W6/SS cross linked B- FABP when refolded and subsequently denatured in 8 M urea.
  • the ra- tio(cEi ⁇ /c B- FABp) indicate that the refolded proteins on average contain 2.20 free solvent exposed cysteines, and in denatured conditions 2.15. In denatured conditions, a total of two out of four free cysteines were expected. These re- suits indicate that one disulphide bridge exists in the protein. 76
  • the Absorbance of 5-thio-2-nitrobenzoic acid (TNB ) absorbance was measured at 412 nm and the concentration was calculated using Lambert-Beers law and a molar extinction coefficient of 14150 M cm .
  • the calculated concentration was compared with the known concentration of B-FABP to find an estimate of the number of solvent exposed and free cysteine residues per B- FABP molecule.
  • Table 6 displays the measured absorbance and the amount of disulphide bridges calculated from the absorbance for the SS tagged B-FABP. It is seen that the proteins on average contain 0.41 free solvent exposed cysteines. This means that there is at least 1 disulphide bridge formed, maybe 2.
  • Light induced protein immobilization W6/SS coupled B-FABP and SS tagged B-FABP were coupled onto an activated quartz surface using a laser system for UV irradiation.
  • the protocols used thereto included surface activation, labeling by fluorescent probe (see previous examples), and light induced protein immobilization by laser.
  • the solution of protein to be immobilized was dispensed onto a thiol activated op- tically flat glass slide.
  • the laser system provided pulses with a duration of 50- 60 fs and a wavelength of 280 nm.
  • the laser focal spot was focused on the surface of the glass slide.
  • the duration of illumination of each spot was 5 seconds and the spot were separated by roughly 500 ⁇ m.
  • After immobilization the slide was washed with 4 ml of 1x PBS solution with 0.1% Tween 20 79
  • Protein/peptide to be immobilized Thiol activated optically flat glass slide; 1x Phosphate buffered saline (PBS); Polyethylene glycol sorbitan monolaurate (Tween 20) (C58H114026), Cas: 9005-64-5, Sigma-Aldrich; MiIIi-Q H2O; Spectra Physics Tsunami 3960 titanium-sapphire laser; Spectra Physics Millennia V solid state laser; Tecan LS 200 Scanner.
  • PBS Phosphate buffered saline
  • Teween 20 Polyethylene glycol sorbitan monolaurate
  • Figure 5 shows two examples of W6/SS cross-linked B-FABP labeled with 5(6)-carboxynaphthofluorescein, immobilized on thiol derivatized quartz slides using UV; (A) 5 X 5 array; (B) 9 X 1 array. Distance between spots: 250 ⁇ m, average spot size: 50 ⁇ m, time of immobilization: 5 seconds/spot. Array visualized with Tecan LS200 Array Scanner. Excitation: 633 nm (red laser). Emission filter: 670 nm. Gain 180. The images were processed in Im- ageJ 1.36b.
  • Figure 6 shows SS cross-linked B-FABP labeled with 5(6)- carboxynaphthofluorescein, immobilized on thiol derivatized quartz slides using UV on a 2 X 5 array; Distance between spots: 250 ⁇ m, average spot size: 50 ⁇ m, time of immobilization: 5 seconds/spot.
  • Figures 5 and 6 demonstrate the successful immobilizations B-FABP to a thiol activated quartz slide via thiol bonds, either chemically coupled or C- terminally extended with a linker, comprising a disulfide bridge-containing triad or an appropriate disulfide bridge, respectively. No immobilization is seen in the areas not illuminated by the laser. Controls were made using native B-FABP and SS tag peptide. Native B-FABP showed no immobilization (not shown). 80
  • HpTX2 Knottin peptide
  • HpTX2 Heteropodatoxin-2
  • PDB 1 EMX
  • HpTX2 consists of 30 amino acids with one Tyr residue at position 20, and two Trp residues at positions 25 and 30. There are three disulphide bridges between residues 3 and 17, 10 and 22, 16 and 26.
  • Figure 22 [www.pdb.org, accessed 05-01-06] shows the structure of HpTX2 (PDB: 1 EMX, solved by NMR); Native HpTX2.
  • Backbone green; Disulphide bridges: yellow sticks; Tyr: red; Trp: blue.
  • Middle Mutated HpTX2 (mutHpTX2), Tyr20 is mutated to Trp (blue), Trp25 is mutated to Phe (or- ange), and Trp30 is deleted.
  • Right The distances from Trp to each disulphide bridge in mutHpTX2 is seen. Images are generated using PyMOL 0.98.
  • HpTX2 was chosen as the length is only 30 amino acids and because it has a Tyr residue buried between the disulphide bridges only 5.71A, 7.53A, and 9.90A from these, see Figure 22. Tyr20 would be mutated to Trp20 because of the higher extinction coefficient of Trp residues [Creighton, 1993]. Furthermore, Trp25 would be substituted by a Phe residue and Trp30 would be removed altogether to ensure that the transmitted energy stems from Trp20 exclusively for the purpose of simplifying the characterization of the peptide upon photo-activation.
  • HpTX2 was first examined in DeepView 3.7, to investigate the impact of mutations on the structure.
  • the basic criteria for examining the mutations was to look at energy minimized conformations to check whether conformers not forming atomic clashes were predicted.
  • Table 7 shows different ⁇ values calculated for possible mutant conformations calculated by DeepView 3.7. The results show that a stable conformation for the HpTX2 Y20W mutant can be expected.
  • Table 7 ⁇ for different conformations calculated using DeepView.
  • the conformations relate to the mutations Tyr20 ⁇ Trp20, and Trp25 ⁇ Phe25.
  • the value of ⁇ corresponds to intramolecular clashes arising from the mutations, for each described conformation.
  • the DNA adapter coding mutHpTX2 can be generated by annealing of self- complementary adapter primers LD035fw (Table 2) and filled-in with Pfu po- lymerase. Restriction sites for BamH ⁇ at the 5'-end and BgIW at the 3'-end are added to the adapter for ligation into pET11 vector and restoration of a BamH ⁇ site in the new vector, for subsequent ligations. An additional Sma ⁇ site is added in 5' for additional flexibility in ligations and a double stop codon is added at the 3'-end to stop translation.
  • the construct with pET-11a utilizes the restriction sites for ⁇ amHI and BgIW.
  • SamHI and BgIW overhangs are compatible, however if the overhangs are ligated the resulting annealing sequence is non-recognizable, i.e. not re- cleavable by BamVW.
  • a ligation mix of the mutant HpTX2-DNA digested with both BambU and BgIW and pET-11a digested with BamHI results in a modified plasmid.
  • the mutant HpTX2-DNA has become an intrinsic part of pET-11a, due to the non-recognizable annealing sequence and a new restriction site for BamHI is created.
  • the insert may be oriented in two directions. It is therefore necessary to ensure that the orientation is correct such that the sequence of the translated DNA reads from N-terminus to C-terminus, thereby having the restriction site for BamHI situated immediately upstream the insert and not vice versa.
  • the re- suit is a construct that allows for the in-frame C-terminal fusion of a protein coding DNA sequence to the mutated HpTX2 by digesting the plasmid and the target gene (insert) with BamHI and Ndel.
  • Double stranded DNA coding the mutHpTX2 gene was generated by annealing to complementary oligonuclotides (LD035fw / LD036rv) and filling the 3' 84
  • PCR primers LD035fw, LD036rv, LD037rv, T7fw, TAGCopenha- gen BamHI restriction enzyme, 10 u/ ⁇ l, Fermentas; BgIII restriction enzyme, 10 u/ ⁇ l, New England BioLabs; Buffer s/Tango with BSA 10x, MBI- Fermentas; pET-11a vector DNA, Novagen; Calf intestine alkaline phos- phatase (CIAP), MBI-Fermentas; 10x reaction buffer (0.1 M Tris-HCI pH 7.5, 0.1 M MgCI2), MBI-Fermentas; T4 DNA ligase, Roche Diagnostics GmbH; Ligation buffer 10x (660 mM Tris-HCI, 50 mM MgCI2, 10 mM Dithioerythritol, 10 mM ATP, pH 7.5), Roche Diagnostics GmbH; Sterile MiIIi-Q H2O.
  • pET-11a plasmid for insertion 2 ⁇ l of pET-11a (1300 ng/ ⁇ l) was digested with 1 ⁇ l BamHI in 20 ⁇ l YVTango buffer and 77 ⁇ l sterile MiIIi-Q H2O for 5 hours at 37°C.
  • the plasmid was cleaned and precipitated by use of phenol- chloroform extraction.
  • the cleaned plasmid was resuspended in 20 ⁇ l of ster- ile MiIIi-Q H2O. 1 ⁇ l was extracted and used for concentration determination by OD measurements.
  • the resuspended digested plasmid pET-11a was dephosphorylated using calf intestine alkaline phosphatase (CIAP) in order to avoid self ligation 18 ⁇ l of plasmid was mixed with 5 ⁇ l of 10x reaction buffer, 26 ⁇ l of sterile MiIIi-Q H2O and 1 ⁇ l of CIAP. The mix was incubated at 37°C for 30 minutes.
  • CIP calf intestine alkaline phosphatase
  • the ligation of the digested mutHpTX2 with the digested dephosphorylated pET-11a was done by mixing 4 ⁇ l of pET-11a (405 ng/ ⁇ l) with 2 ⁇ l of mutHpTX2 (67.5 ng/ ⁇ l) and 2 ⁇ l ligation buffer, 2 ⁇ l T4 ligase and 10 ⁇ l sterile MiIIi-Q H2O. The mix was incubated at 12°C for 72 hours and following inactivated at 65°C for 10 minutes. The ligated plasmid was trans- formed into competent E. coli DH5 ⁇ cells and plated onto LBAmp 100 plates and incubated at 37°C overnight.
  • the Sma ⁇ restriction site, in the mutant HpTX2-DNA sequence was designed to be used with the pET-43.1a plasmid along with a BgIIl site.
  • This plasmid is designed for high-level expression of recombinant proteins, by fusing them with the highly expressed, highly cyto-soluble Nus protein (495 AA), to gen- erate a so-called Nus-Taq.
  • Digesting pET-43.1a and the adapter peptide with Sma ⁇ and BgIW fuses mutHpTX2 DNA to Nus. This construct allows thereby 86
  • the samples were inactivated by heating to 65°C for 10 minutes.
  • the ligated constructs were transformed into competent E. coli DH5 ⁇ cells, and following plated onto LB-Amp 100 plates and incubated at 37 0 C overnight. After incubation 20 colonies were picked and replated onto a new LB Amp 100 plate and left at 37 0 C over night. The replated colonies were subjected to a 87
  • BamHI restriction enzyme 10 u/ ⁇ l, Fermentas; NcIeIII restriction enzyme, 20 u/ ⁇ l, New England BioLabs; Buffer Y + /Tango with BSA 10x, MBI- Fermentas; T4 DNA ligase, Roche Diagnostics GmbH; Ligation buffer 10x (660 mM Tris-HCI, 50 mM MgCI2, 10 mM Dithioerythritol, 10 mM ATP, pH 7.5), Roche Diagnostics GmbH; Sterile MiIIi-Q H2O.
  • FIG. 26 shows a 1.5% agarose gel with DNA from a colony PCR using primers T7fw and LD037rv on pET-11a ligated with mutHpTX2.
  • Lane 1 and 14 holds a 100 bp ladder, while lane 6, 10, and 12 corresponds to colony 8, 1 and 17 respectively. Bands corresponding to products of -300 bp length are found for colonies 8 and 17, while a band corresponding to a ⁇ 220 bp prod- uct is found for colony 1.
  • a PCR using these two primers and pET11-a with mutHpTX2 should yield a 226 bp product. It is expected that colony 1 has the correct insert, however as none of the clones were sequenced it was decided to keep all three colonies at this point. Conclusive evidence requires sequencing of the clones.
  • FBPs fatty acid-binding proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé de couplage induit par la lumière de deux éléments A et B par l'intermédiaire d'une liaison thiol. Selon le procédé, des molécules, des protéines, des peptides ou des éléments contenant des peptides peuvent être couplés à un support ou à une seconde molécule, protéine, peptide ou élément contenant un peptide, les propriétés structurales et fonctionnelles des éléments couplés ou immobilisés étant conservées, et l'orientation du couplage pouvant être réglée à une échelle moléculaire. En particulier, le procédé comporte la génération d'un élément A* par la disposition sur ledit élément A d'un pont disulfure approprié ou d'une triade appropriée contenant un pont disulfure, l'irradiation de l'élément A* pour créer un groupe thiol réactif approprié à partir de la liaison disulfure, et l'incubation de l'élément irradié A* avec ledit élément B, permettant ainsi d'obtenir un couplage entre l'élément A et l'élément B. En variante, l'élément A* peut également être irradié en présence de B.
PCT/DK2007/000569 2006-12-22 2007-12-21 Couplage d'éléments Ceased WO2008077406A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87667306P 2006-12-22 2006-12-22
US60/876,673 2006-12-22

Publications (2)

Publication Number Publication Date
WO2008077406A2 true WO2008077406A2 (fr) 2008-07-03
WO2008077406A3 WO2008077406A3 (fr) 2008-08-21

Family

ID=39415145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/000569 Ceased WO2008077406A2 (fr) 2006-12-22 2007-12-21 Couplage d'éléments

Country Status (1)

Country Link
WO (1) WO2008077406A2 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8956603B2 (en) 2009-02-21 2015-02-17 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US8968818B2 (en) 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US9272074B2 (en) 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
US9375699B2 (en) 2009-02-21 2016-06-28 Sofradim Production Apparatus and method of reacting polymers by exposure to UV radiation to produce injectable medical devices
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
US9555154B2 (en) 2009-02-21 2017-01-31 Covidien Lp Medical devices having activated surfaces
WO2017075863A1 (fr) * 2015-11-05 2017-05-11 盘古基因生物工程(南京)股份有限公司 Vecteur d'expression de protéine hybride de protéine du type chaperon
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
US9987297B2 (en) 2010-07-27 2018-06-05 Sofradim Production Polymeric fibers having tissue reactive members

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2137561C (fr) * 1992-07-06 2001-10-23 Thomas R. Sykes Photoactivation de proteines en vue de leur conjugaison
ATE410450T1 (de) * 2003-01-22 2008-10-15 Bionanophotonics As Licht-induzierte immobilisierung
WO2007000163A1 (fr) * 2005-06-27 2007-01-04 Bionanophotonics A/S Immobilisation de polypeptides par irradiation

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
US9375699B2 (en) 2009-02-21 2016-06-28 Sofradim Production Apparatus and method of reacting polymers by exposure to UV radiation to produce injectable medical devices
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US10632207B2 (en) 2009-02-21 2020-04-28 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US10167371B2 (en) 2009-02-21 2019-01-01 Covidien Lp Medical devices having activated surfaces
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8956603B2 (en) 2009-02-21 2015-02-17 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US8968818B2 (en) 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US9216226B2 (en) 2009-02-21 2015-12-22 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US9555154B2 (en) 2009-02-21 2017-01-31 Covidien Lp Medical devices having activated surfaces
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US9550164B2 (en) 2009-02-21 2017-01-24 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US9510810B2 (en) 2009-02-21 2016-12-06 Sofradim Production Medical devices incorporating functional adhesives
US9421296B2 (en) 2009-02-21 2016-08-23 Covidien Lp Crosslinked fibers and method of making same by extrusion
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US9511175B2 (en) 2009-02-21 2016-12-06 Sofradim Production Medical devices with an activated coating
US9517291B2 (en) 2009-02-21 2016-12-13 Covidien Lp Medical devices having activated surfaces
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
US9272074B2 (en) 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
US9554782B2 (en) 2010-03-25 2017-01-31 Covidien Lp Medical devices incorporating functional adhesives
US10143471B2 (en) 2010-03-25 2018-12-04 Sofradim Production Surgical fasteners and methods for sealing wounds
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US9987297B2 (en) 2010-07-27 2018-06-05 Sofradim Production Polymeric fibers having tissue reactive members
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
WO2017075863A1 (fr) * 2015-11-05 2017-05-11 盘古基因生物工程(南京)股份有限公司 Vecteur d'expression de protéine hybride de protéine du type chaperon

Also Published As

Publication number Publication date
WO2008077406A3 (fr) 2008-08-21

Similar Documents

Publication Publication Date Title
WO2008077406A2 (fr) Couplage d'éléments
Tse Sum Bui et al. Molecularly imprinted polymers as synthetic antibodies for protein recognition: the next generation
Cheloha et al. Improved GPCR ligands from nanobody tethering
CN1295510C (zh) 利用o6－烷基鸟嘌呤－dna烷基转移酶的方法
CN105073770B (zh) 链霉亲和素突变蛋白及其使用方法
KR101477123B1 (ko) 항체결합 펩타이드-페리틴 융합단백질 및 이의 용도
CN120718997A (zh) 产生纳米阵列和微阵列的方法
JP6057904B2 (ja) 有機ターゲットに結合するためのクモ糸融合タンパク質構造
Meredith et al. Targeted protein functionalization using His-tags
JP5066615B2 (ja) フェニルボロン酸基と特異的に結合するオリゴペプチド配列
JP2025162556A (ja) 多分子ルシフェラーゼペプチド及びポリペプチド
Algar et al. Synthesizing and modifying peptides for chemoselective ligation and assembly into quantum dot-peptide bioconjugates
KR101104417B1 (ko) 단백질 ｇ 변형체를 이용한 항체의 특이적 공유결합 커플링방법
JP2000510454A (ja) カルシウム依存性結合タンパク質の改変されたリガンド
Yuca et al. In vitro labeling of hydroxyapatite minerals by an engineered protein
Wei et al. Adsorption-induced changes in ribonuclease A structure and enzymatic activity on solid surfaces
KR20150080417A (ko) 링커를 통해 연결된 동일한 표적 물질에 결합하는 항체 및 앱타머를 포함하는 집게 분자 및 이의 용도
Pane et al. Chemical cleavage of an Asp-Cys sequence allows efficient production of recombinant peptides with an N-terminal cysteine residue
Zhao et al. Site-specific modification of a single-chain antibody using a novel glyoxylyl-based labeling reagent
JP6484607B2 (ja) アフィニティー樹脂を使用するａｄｃの合成方法
EP1587839B1 (fr) Immobilisation photogeneree
Dirvelyte et al. Genetically encoded phosphatidylserine biosensor for in vitro, ex vivo and in vivo labelling
Xie et al. Chemical synthesis of proteins using an o-nitrobenzyl group as a robust temporary protective group for N-terminal cysteine protection
Ramakrishnan et al. Engineered adhesion peptides for improved silicon adsorption
US20100216969A1 (en) Immobilisation of polypeptides by irradiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07846439

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07846439

Country of ref document: EP

Kind code of ref document: A2